source,target,relation,sentence,doi
infection,viral infections,unknown,Tetramer staining of human PBMCs enriched CD4 T memory populations from healthy adult subjects highlighting this approach as a sensitive and specific method of identifying novel epitopes and subsequent CD4 T cell responses to human viral infections.,10.1101/2025.10.16.682991
trametinib,sorafenib,unknown,"We identified four host-directed drugs, donepezil, dH-ergocristine, trametinib and sorafenib, that could potentially be repurposed to treat coronavirus infections.",10.1101/2025.10.15.682635
trametinib,coronavirus infections,unknown,"We identified four host-directed drugs, donepezil, dH-ergocristine, trametinib and sorafenib, that could potentially be repurposed to treat coronavirus infections.",10.1101/2025.10.15.682635
sorafenib,coronavirus infections,unknown,"We identified four host-directed drugs, donepezil, dH-ergocristine, trametinib and sorafenib, that could potentially be repurposed to treat coronavirus infections.",10.1101/2025.10.15.682635
Tyrosine,pan-coronaviruses infection,unknown,"Here, we performed a genome-wide CRISPRi screening to identify the host protein, Hepatocyte Growth Factor-Regulated Tyrosine Kinase Substrate (HGS), as essential for the pan-coronaviruses infection both in vitro and in vivo.",10.1101/2025.10.17.683077
riboflavin tetrabutyrate,RTB,unknown,"Leveraging this interaction, we designed M-derived peptides and screened over 5,000 FDA-approved drugs, identifying riboflavin tetrabutyrate (RTB).",10.1101/2025.10.17.683077
riboflavin tetrabutyrate,RTB,unknown,"Leveraging this interaction, we designed M-derived peptides and screened over 5,000 FDA-approved drugs, identifying riboflavin tetrabutyrate (RTB).",10.1101/2025.10.17.683077
riboflavin tetrabutyrate,RTB,unknown,"Leveraging this interaction, we designed M-derived peptides and screened over 5,000 FDA-approved drugs, identifying riboflavin tetrabutyrate (RTB).",10.1101/2025.10.17.683077
RTB,RTB,unknown,"Leveraging this interaction, we designed M-derived peptides and screened over 5,000 FDA-approved drugs, identifying riboflavin tetrabutyrate (RTB).",10.1101/2025.10.17.683077
RTB,RTB,unknown,"Leveraging this interaction, we designed M-derived peptides and screened over 5,000 FDA-approved drugs, identifying riboflavin tetrabutyrate (RTB).",10.1101/2025.10.17.683077
RTB,RTB,unknown,"Leveraging this interaction, we designed M-derived peptides and screened over 5,000 FDA-approved drugs, identifying riboflavin tetrabutyrate (RTB).",10.1101/2025.10.17.683077
RTB,RTB,unknown,"Both the peptides and RTB bind HGS and disrupt its interaction with the M protein, leading to M retention in the ER and subsequent blockade of virion assembly.",10.1101/2025.10.17.683077
RTB,RTB,unknown,"Both the peptides and RTB bind HGS and disrupt its interaction with the M protein, leading to M retention in the ER and subsequent blockade of virion assembly.",10.1101/2025.10.17.683077
RTB,RTB,unknown,"Both the peptides and RTB bind HGS and disrupt its interaction with the M protein, leading to M retention in the ER and subsequent blockade of virion assembly.",10.1101/2025.10.17.683077
RTB,RTB,unknown,"Collectively, our findings establish HGS as a druggable host target and identify RTB as a promising broad-spectrum antiviral candidate.",10.1101/2025.10.17.683077
RTB,RTB,unknown,"Collectively, our findings establish HGS as a druggable host target and identify RTB as a promising broad-spectrum antiviral candidate.",10.1101/2025.10.17.683077
RTB,RTB,unknown,"Collectively, our findings establish HGS as a druggable host target and identify RTB as a promising broad-spectrum antiviral candidate.",10.1101/2025.10.17.683077
nilotinib,tecovirimat,unknown,One top-ranked drug nilotinib is experimentally shown to have a significant 69% of antiviral efficacy of the FDA-approved antiviral tecovirimat (TPOXX(R) or ST-246).,10.1101/2025.10.12.681938
nilotinib,ST-246,unknown,One top-ranked drug nilotinib is experimentally shown to have a significant 69% of antiviral efficacy of the FDA-approved antiviral tecovirimat (TPOXX(R) or ST-246).,10.1101/2025.10.12.681938
tecovirimat,ST-246,unknown,One top-ranked drug nilotinib is experimentally shown to have a significant 69% of antiviral efficacy of the FDA-approved antiviral tecovirimat (TPOXX(R) or ST-246).,10.1101/2025.10.12.681938
SARS-CoV-2 infection,SARS-CoV-2 infection,unknown,"We recently described AVI-4206 (1), a potent and selective inhibitor of the SARS-CoV-2 ADP-ribosylhydrolase Mac1 based on a 9H-pyrimido[4,5-b]indole core, the first Mac1 inhibitor to demonstrate antiviral efficacy in mouse models of SARS-CoV-2 infection, but requiring IP administration and frequent dosing.",10.1101/2025.10.11.681833
urea,hydrogen bond donor,unknown,"Multiple strategies were pursued to overcome these issues, including replacing a urea function to reduce hydrogen bond donor count.",10.1101/2025.10.11.681833
urea,urea,unknown,"Multiple strategies were pursued to overcome these issues, including replacing a urea function to reduce hydrogen bond donor count.",10.1101/2025.10.11.681833
hydrogen bond donor,urea,unknown,"Multiple strategies were pursued to overcome these issues, including replacing a urea function to reduce hydrogen bond donor count.",10.1101/2025.10.11.681833
urea,urea,unknown,"While heterocyclic urea mimetics could deliver analogs like AVI-6318 (3) with potencies and ADME profiles similar to 1, abrogation of the P-gp liability was finally achieved with entirely non-polar substituents in place of urea.",10.1101/2025.10.11.681833
SARS-CoV-2 infection,once-daily,unknown,"Thus, AVI-6451 (4) is a potent Mac1 inhibitor lead with low intrinsic clearance, high oral bioavailability, and antiviral efficacy with once-daily oral administration in a mouse model of SARS-CoV-2 infection.",10.1101/2025.10.11.681833
SARS-CoV-2 infection,SARS-CoV-2 infection,unknown,"Thus, AVI-6451 (4) is a potent Mac1 inhibitor lead with low intrinsic clearance, high oral bioavailability, and antiviral efficacy with once-daily oral administration in a mouse model of SARS-CoV-2 infection.",10.1101/2025.10.11.681833
once-daily,SARS-CoV-2 infection,unknown,"Thus, AVI-6451 (4) is a potent Mac1 inhibitor lead with low intrinsic clearance, high oral bioavailability, and antiviral efficacy with once-daily oral administration in a mouse model of SARS-CoV-2 infection.",10.1101/2025.10.11.681833
uridine,ARCA,unknown,We examined different combinations of linear vectors: containing either N1-methylpseudouridines or uridine and capped with either ARCA (m7G(5')ppp(5')G) or CleanCap (m7G(5')ppp(5')m2G).,10.1101/2025.10.13.682008
PASC,infection,unknown,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101
PASC,PASC,unknown,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101
PASC,infection,unknown,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101
PASC,PASC,unknown,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101
PASC,infection,unknown,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101
PASC,PASC,unknown,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101
PASC,PASC,unknown,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101
infection,PASC,unknown,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101
infection,infection,unknown,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101
infection,PASC,unknown,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101
infection,infection,unknown,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101
infection,PASC,unknown,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101
infection,PASC,unknown,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101
PASC,infection,unknown,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101
PASC,PASC,unknown,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101
PASC,infection,unknown,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101
PASC,PASC,unknown,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101
PASC,PASC,unknown,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101
infection,PASC,unknown,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101
infection,infection,unknown,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101
infection,PASC,unknown,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101
infection,PASC,unknown,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101
PASC,infection,unknown,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101
PASC,PASC,unknown,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101
PASC,PASC,unknown,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101
infection,PASC,unknown,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101
infection,PASC,unknown,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101
PASC,PASC,unknown,"While males are more likely to suffer severe outcomes during acute COVID-19, a greater proportion of females develop post-acute sequalae of COVID-19 (PASC) despite similar rates of infection.",10.1101/2025.10.13.682101
PASC,infection,unknown,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101
PASC,PASC,unknown,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101
PASC,infected with SARS-CoV-2 and viral,unknown,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101
PASC,infection,unknown,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101
PASC,PASC,unknown,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101
PASC,infection,unknown,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101
PASC,PASC,unknown,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101
PASC,PASC,unknown,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101
infection,PASC,unknown,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101
infection,infected with SARS-CoV-2 and viral,unknown,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101
infection,infection,unknown,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101
infection,PASC,unknown,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101
infection,infection,unknown,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101
infection,PASC,unknown,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101
infection,PASC,unknown,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101
PASC,infected with SARS-CoV-2 and viral,unknown,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101
PASC,infection,unknown,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101
PASC,PASC,unknown,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101
PASC,infection,unknown,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101
PASC,PASC,unknown,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101
PASC,PASC,unknown,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101
infected with SARS-CoV-2 and viral,infection,unknown,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101
infected with SARS-CoV-2 and viral,PASC,unknown,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101
infected with SARS-CoV-2 and viral,infection,unknown,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101
infected with SARS-CoV-2 and viral,PASC,unknown,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101
infected with SARS-CoV-2 and viral,PASC,unknown,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101
infection,PASC,unknown,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101
infection,infection,unknown,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101
infection,PASC,unknown,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101
infection,PASC,unknown,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101
PASC,infection,unknown,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101
PASC,PASC,unknown,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101
PASC,PASC,unknown,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101
infection,PASC,unknown,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101
infection,PASC,unknown,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101
PASC,PASC,unknown,"To identify mechanisms of PASC, mice were infected with SARS-CoV-2 and viral, inflammatory, and behavioral outcomes were evaluated through 84 days post infection.",10.1101/2025.10.13.682101
PASC,PASC,unknown,Sex differences were not observed in virus replication or persistence of viral RNA in pulmonary or extrapulmonary tissues in acute or PASC phases.,10.1101/2025.10.13.682101
PASC,PASC,unknown,Sex differences were not observed in virus replication or persistence of viral RNA in pulmonary or extrapulmonary tissues in acute or PASC phases.,10.1101/2025.10.13.682101
PASC,PASC,unknown,Sex differences were not observed in virus replication or persistence of viral RNA in pulmonary or extrapulmonary tissues in acute or PASC phases.,10.1101/2025.10.13.682101
PASC,PASC,unknown,Sex differences were not observed in virus replication or persistence of viral RNA in pulmonary or extrapulmonary tissues in acute or PASC phases.,10.1101/2025.10.13.682101
PASC,PASC,unknown,Sex differences were not observed in virus replication or persistence of viral RNA in pulmonary or extrapulmonary tissues in acute or PASC phases.,10.1101/2025.10.13.682101
PASC,PASC,unknown,Sex differences were not observed in virus replication or persistence of viral RNA in pulmonary or extrapulmonary tissues in acute or PASC phases.,10.1101/2025.10.13.682101
PASC,PASC,unknown,Sex differences were not observed in virus replication or persistence of viral RNA in pulmonary or extrapulmonary tissues in acute or PASC phases.,10.1101/2025.10.13.682101
PASC,PASC,unknown,Sex differences were not observed in virus replication or persistence of viral RNA in pulmonary or extrapulmonary tissues in acute or PASC phases.,10.1101/2025.10.13.682101
PASC,PASC,unknown,Sex differences were not observed in virus replication or persistence of viral RNA in pulmonary or extrapulmonary tissues in acute or PASC phases.,10.1101/2025.10.13.682101
PASC,PASC,unknown,Sex differences were not observed in virus replication or persistence of viral RNA in pulmonary or extrapulmonary tissues in acute or PASC phases.,10.1101/2025.10.13.682101
infection,infection,unknown,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101
infection,infection,unknown,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101
infection,neurocognitive and behavioral impairments,unknown,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101
infection,neuroinflammation,unknown,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101
infection,inflammation,unknown,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101
infection,neuroinflammation,unknown,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101
infection,inflammation,unknown,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101
infection,infection,unknown,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101
infection,neurocognitive and behavioral impairments,unknown,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101
infection,neuroinflammation,unknown,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101
infection,inflammation,unknown,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101
infection,neuroinflammation,unknown,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101
infection,inflammation,unknown,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101
infection,neurocognitive and behavioral impairments,unknown,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101
infection,neuroinflammation,unknown,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101
infection,inflammation,unknown,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101
infection,neuroinflammation,unknown,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101
infection,inflammation,unknown,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101
neurocognitive and behavioral impairments,neuroinflammation,unknown,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101
neurocognitive and behavioral impairments,inflammation,unknown,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101
neurocognitive and behavioral impairments,neuroinflammation,unknown,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101
neurocognitive and behavioral impairments,inflammation,unknown,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101
neuroinflammation,inflammation,unknown,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101
neuroinflammation,neuroinflammation,unknown,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101
neuroinflammation,inflammation,unknown,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101
inflammation,neuroinflammation,unknown,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101
inflammation,inflammation,unknown,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101
neuroinflammation,inflammation,unknown,"Following recovery from infection, female mice exhibited persistent neurocognitive and behavioral impairments, along with greater frequencies of inflammatory myeloid subsets, neuroinflammation, and dysregulated T cell subsets, including Tregs.",10.1101/2025.10.13.682101
PASC,PASC,unknown,Sex differences in inflammation and cognitive phenotypes during PASC were mediated by the presence of two X chromosomes.,10.1101/2025.10.13.682101
PASC,PASC,unknown,Sex differences in inflammation and cognitive phenotypes during PASC were mediated by the presence of two X chromosomes.,10.1101/2025.10.13.682101
PASC,inflammation,unknown,Sex differences in inflammation and cognitive phenotypes during PASC were mediated by the presence of two X chromosomes.,10.1101/2025.10.13.682101
PASC,PASC,unknown,Sex differences in inflammation and cognitive phenotypes during PASC were mediated by the presence of two X chromosomes.,10.1101/2025.10.13.682101
PASC,PASC,unknown,Sex differences in inflammation and cognitive phenotypes during PASC were mediated by the presence of two X chromosomes.,10.1101/2025.10.13.682101
PASC,inflammation,unknown,Sex differences in inflammation and cognitive phenotypes during PASC were mediated by the presence of two X chromosomes.,10.1101/2025.10.13.682101
PASC,PASC,unknown,Sex differences in inflammation and cognitive phenotypes during PASC were mediated by the presence of two X chromosomes.,10.1101/2025.10.13.682101
PASC,inflammation,unknown,Sex differences in inflammation and cognitive phenotypes during PASC were mediated by the presence of two X chromosomes.,10.1101/2025.10.13.682101
PASC,PASC,unknown,Sex differences in inflammation and cognitive phenotypes during PASC were mediated by the presence of two X chromosomes.,10.1101/2025.10.13.682101
PASC,PASC,unknown,Sex differences in inflammation and cognitive phenotypes during PASC were mediated by the presence of two X chromosomes.,10.1101/2025.10.13.682101
PASC,inflammation,unknown,Sex differences in inflammation and cognitive phenotypes during PASC were mediated by the presence of two X chromosomes.,10.1101/2025.10.13.682101
PASC,inflammation,unknown,Sex differences in inflammation and cognitive phenotypes during PASC were mediated by the presence of two X chromosomes.,10.1101/2025.10.13.682101
PASC,PASC,unknown,Sex differences in inflammation and cognitive phenotypes during PASC were mediated by the presence of two X chromosomes.,10.1101/2025.10.13.682101
PASC,PASC,unknown,Sex differences in inflammation and cognitive phenotypes during PASC were mediated by the presence of two X chromosomes.,10.1101/2025.10.13.682101
PASC,inflammation,unknown,Sex differences in inflammation and cognitive phenotypes during PASC were mediated by the presence of two X chromosomes.,10.1101/2025.10.13.682101
inflammation,PASC,unknown,Sex differences in inflammation and cognitive phenotypes during PASC were mediated by the presence of two X chromosomes.,10.1101/2025.10.13.682101
inflammation,PASC,unknown,Sex differences in inflammation and cognitive phenotypes during PASC were mediated by the presence of two X chromosomes.,10.1101/2025.10.13.682101
inflammation,inflammation,unknown,Sex differences in inflammation and cognitive phenotypes during PASC were mediated by the presence of two X chromosomes.,10.1101/2025.10.13.682101
PASC,PASC,unknown,Sex differences in inflammation and cognitive phenotypes during PASC were mediated by the presence of two X chromosomes.,10.1101/2025.10.13.682101
PASC,inflammation,unknown,Sex differences in inflammation and cognitive phenotypes during PASC were mediated by the presence of two X chromosomes.,10.1101/2025.10.13.682101
PASC,inflammation,unknown,Sex differences in inflammation and cognitive phenotypes during PASC were mediated by the presence of two X chromosomes.,10.1101/2025.10.13.682101
PASC,infection,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
PASC,PASC,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
PASC,infection,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
PASC,PASC,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
PASC,infection,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
PASC,neuroinflammation,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
PASC,inflammation,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
PASC,PASC,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
PASC,neuroinflammation,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
PASC,PASC,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
PASC,inflammation,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
PASC,chronic disease,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
infection,PASC,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
infection,infection,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
infection,PASC,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
infection,infection,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
infection,neuroinflammation,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
infection,inflammation,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
infection,PASC,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
infection,neuroinflammation,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
infection,PASC,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
infection,inflammation,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
infection,chronic disease,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
PASC,infection,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
PASC,PASC,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
PASC,infection,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
PASC,neuroinflammation,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
PASC,inflammation,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
PASC,PASC,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
PASC,neuroinflammation,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
PASC,PASC,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
PASC,inflammation,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
PASC,chronic disease,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
infection,PASC,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
infection,infection,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
infection,neuroinflammation,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
infection,inflammation,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
infection,PASC,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
infection,neuroinflammation,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
infection,PASC,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
infection,inflammation,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
infection,chronic disease,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
PASC,infection,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
PASC,neuroinflammation,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
PASC,inflammation,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
PASC,PASC,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
PASC,neuroinflammation,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
PASC,PASC,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
PASC,inflammation,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
PASC,chronic disease,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
infection,neuroinflammation,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
infection,inflammation,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
infection,PASC,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
infection,neuroinflammation,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
infection,PASC,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
infection,inflammation,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
infection,chronic disease,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
neuroinflammation,inflammation,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
neuroinflammation,PASC,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
neuroinflammation,neuroinflammation,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
neuroinflammation,PASC,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
neuroinflammation,inflammation,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
neuroinflammation,chronic disease,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
inflammation,PASC,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
inflammation,neuroinflammation,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
inflammation,PASC,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
inflammation,inflammation,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
inflammation,chronic disease,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
PASC,neuroinflammation,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
PASC,PASC,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
PASC,inflammation,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
PASC,chronic disease,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
neuroinflammation,PASC,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
neuroinflammation,inflammation,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
neuroinflammation,chronic disease,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
PASC,inflammation,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
PASC,chronic disease,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
inflammation,chronic disease,unknown,XX animals independent of chromosome Y presented with neuroinflammation and PASC along with infection-induced upregulation of the X-linked genes Xist and Tlr7 that regulate inflammation and chronic disease outcomes.,10.1101/2025.10.13.682101
infection,infection,unknown,The relationship between the extracellular matrix and the host immune response to infection is severely understudied.,10.1101/2025.10.13.682000
infection,anti-CD44,unknown,"Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection.",10.1101/2025.10.13.682000
infection,weight loss,unknown,"Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection.",10.1101/2025.10.13.682000
infection,infection,unknown,"Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection.",10.1101/2025.10.13.682000
infection,anti-CD44,unknown,"Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection.",10.1101/2025.10.13.682000
infection,anti-CD44,unknown,"Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection.",10.1101/2025.10.13.682000
infection,anti-CD44,unknown,"Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection.",10.1101/2025.10.13.682000
anti-CD44,weight loss,unknown,"Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection.",10.1101/2025.10.13.682000
anti-CD44,infection,unknown,"Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection.",10.1101/2025.10.13.682000
anti-CD44,anti-CD44,unknown,"Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection.",10.1101/2025.10.13.682000
anti-CD44,anti-CD44,unknown,"Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection.",10.1101/2025.10.13.682000
anti-CD44,anti-CD44,unknown,"Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection.",10.1101/2025.10.13.682000
weight loss,infection,unknown,"Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection.",10.1101/2025.10.13.682000
weight loss,anti-CD44,unknown,"Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection.",10.1101/2025.10.13.682000
weight loss,anti-CD44,unknown,"Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection.",10.1101/2025.10.13.682000
weight loss,anti-CD44,unknown,"Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection.",10.1101/2025.10.13.682000
infection,anti-CD44,unknown,"Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection.",10.1101/2025.10.13.682000
infection,anti-CD44,unknown,"Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection.",10.1101/2025.10.13.682000
infection,anti-CD44,unknown,"Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection.",10.1101/2025.10.13.682000
anti-CD44,anti-CD44,unknown,"Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection.",10.1101/2025.10.13.682000
anti-CD44,anti-CD44,unknown,"Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection.",10.1101/2025.10.13.682000
anti-CD44,anti-CD44,unknown,"Here, we report that in mice infected with a mouse-adapted strain of SARS-CoV-2, treatment with a combination of two anti-CD44 monoclonal antibodies confers a significant survival benefit and reduces weight loss and clinical score of the mice on Day 4 post infection.",10.1101/2025.10.13.682000
anti-CD44,anti-CD44,unknown,We show that anti-CD44 treatment decreases many key cytokines and chemokines in the bronchoalveolar lavage fluid on Day 4.,10.1101/2025.10.13.682000
anti-CD44,anti-CD44,unknown,We show that anti-CD44 treatment decreases many key cytokines and chemokines in the bronchoalveolar lavage fluid on Day 4.,10.1101/2025.10.13.682000
anti-CD44,anti-CD44,unknown,We show that anti-CD44 treatment decreases many key cytokines and chemokines in the bronchoalveolar lavage fluid on Day 4.,10.1101/2025.10.13.682000
anti-CD44,anti-CD44,unknown,We show that anti-CD44 treatment decreases many key cytokines and chemokines in the bronchoalveolar lavage fluid on Day 4.,10.1101/2025.10.13.682000
anti-CD44,anti-CD44,unknown,We show that anti-CD44 treatment decreases many key cytokines and chemokines in the bronchoalveolar lavage fluid on Day 4.,10.1101/2025.10.13.682000
anti-CD44,anti-CD44,unknown,We show that anti-CD44 treatment decreases many key cytokines and chemokines in the bronchoalveolar lavage fluid on Day 4.,10.1101/2025.10.13.682000
anti-CD44,anti-CD44,unknown,"With flow cytometry, we show that anti-CD44 reduces the numbers of neutrophils in infected lungs.",10.1101/2025.10.13.682000
anti-CD44,anti-CD44,unknown,"With flow cytometry, we show that anti-CD44 reduces the numbers of neutrophils in infected lungs.",10.1101/2025.10.13.682000
anti-CD44,anti-CD44,unknown,"With flow cytometry, we show that anti-CD44 reduces the numbers of neutrophils in infected lungs.",10.1101/2025.10.13.682000
anti-CD44,anti-CD44,unknown,"With flow cytometry, we show that anti-CD44 reduces the numbers of neutrophils in infected lungs.",10.1101/2025.10.13.682000
anti-CD44,anti-CD44,unknown,"With flow cytometry, we show that anti-CD44 reduces the numbers of neutrophils in infected lungs.",10.1101/2025.10.13.682000
anti-CD44,anti-CD44,unknown,"With flow cytometry, we show that anti-CD44 reduces the numbers of neutrophils in infected lungs.",10.1101/2025.10.13.682000
anti-CD44,anti-CD44,unknown,"We also show through immunofluorescence that treatment with anti-CD44 antibodies reduces colocalization of HA and CD45 in lung sections, indicating that HAs interaction with immune cells contributes to pathology.",10.1101/2025.10.13.682000
anti-CD44,anti-CD44,unknown,"We also show through immunofluorescence that treatment with anti-CD44 antibodies reduces colocalization of HA and CD45 in lung sections, indicating that HAs interaction with immune cells contributes to pathology.",10.1101/2025.10.13.682000
anti-CD44,anti-CD44,unknown,"We also show through immunofluorescence that treatment with anti-CD44 antibodies reduces colocalization of HA and CD45 in lung sections, indicating that HAs interaction with immune cells contributes to pathology.",10.1101/2025.10.13.682000
anti-CD44,anti-CD44,unknown,"We also show through immunofluorescence that treatment with anti-CD44 antibodies reduces colocalization of HA and CD45 in lung sections, indicating that HAs interaction with immune cells contributes to pathology.",10.1101/2025.10.13.682000
anti-CD44,anti-CD44,unknown,"We also show through immunofluorescence that treatment with anti-CD44 antibodies reduces colocalization of HA and CD45 in lung sections, indicating that HAs interaction with immune cells contributes to pathology.",10.1101/2025.10.13.682000
anti-CD44,anti-CD44,unknown,"We also show through immunofluorescence that treatment with anti-CD44 antibodies reduces colocalization of HA and CD45 in lung sections, indicating that HAs interaction with immune cells contributes to pathology.",10.1101/2025.10.13.682000
infection,infection,unknown,Our findings demonstrate that disruption of HA-receptor interactions is a way to prevent inflammatory pathology in pulmonary infection.,10.1101/2025.10.13.682000
infection,pulmonary infection,unknown,Our findings demonstrate that disruption of HA-receptor interactions is a way to prevent inflammatory pathology in pulmonary infection.,10.1101/2025.10.13.682000
infection,pulmonary infection,unknown,Our findings demonstrate that disruption of HA-receptor interactions is a way to prevent inflammatory pathology in pulmonary infection.,10.1101/2025.10.13.682000
mucormycosis,diabetes,unknown,"During COVID-19 pandemic, the cases of mucormycosis increased substantially, with rhino-orbito-cerebral form linked to uncontrolled diabetes being the predominant manifestation.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"During COVID-19 pandemic, the cases of mucormycosis increased substantially, with rhino-orbito-cerebral form linked to uncontrolled diabetes being the predominant manifestation.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"During COVID-19 pandemic, the cases of mucormycosis increased substantially, with rhino-orbito-cerebral form linked to uncontrolled diabetes being the predominant manifestation.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"During COVID-19 pandemic, the cases of mucormycosis increased substantially, with rhino-orbito-cerebral form linked to uncontrolled diabetes being the predominant manifestation.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"During COVID-19 pandemic, the cases of mucormycosis increased substantially, with rhino-orbito-cerebral form linked to uncontrolled diabetes being the predominant manifestation.",10.1101/2025.10.13.681985
diabetes,mucormycosis,unknown,"During COVID-19 pandemic, the cases of mucormycosis increased substantially, with rhino-orbito-cerebral form linked to uncontrolled diabetes being the predominant manifestation.",10.1101/2025.10.13.681985
diabetes,mucormycosis,unknown,"During COVID-19 pandemic, the cases of mucormycosis increased substantially, with rhino-orbito-cerebral form linked to uncontrolled diabetes being the predominant manifestation.",10.1101/2025.10.13.681985
diabetes,mucormycosis,unknown,"During COVID-19 pandemic, the cases of mucormycosis increased substantially, with rhino-orbito-cerebral form linked to uncontrolled diabetes being the predominant manifestation.",10.1101/2025.10.13.681985
diabetes,mucormycosis,unknown,"During COVID-19 pandemic, the cases of mucormycosis increased substantially, with rhino-orbito-cerebral form linked to uncontrolled diabetes being the predominant manifestation.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"During COVID-19 pandemic, the cases of mucormycosis increased substantially, with rhino-orbito-cerebral form linked to uncontrolled diabetes being the predominant manifestation.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"During COVID-19 pandemic, the cases of mucormycosis increased substantially, with rhino-orbito-cerebral form linked to uncontrolled diabetes being the predominant manifestation.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"During COVID-19 pandemic, the cases of mucormycosis increased substantially, with rhino-orbito-cerebral form linked to uncontrolled diabetes being the predominant manifestation.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"During COVID-19 pandemic, the cases of mucormycosis increased substantially, with rhino-orbito-cerebral form linked to uncontrolled diabetes being the predominant manifestation.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"During COVID-19 pandemic, the cases of mucormycosis increased substantially, with rhino-orbito-cerebral form linked to uncontrolled diabetes being the predominant manifestation.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"During COVID-19 pandemic, the cases of mucormycosis increased substantially, with rhino-orbito-cerebral form linked to uncontrolled diabetes being the predominant manifestation.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
zinc,mucormycosis,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
zinc,mucormycosis,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
zinc,mucormycosis,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
zinc,mucormycosis,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
zinc,mucormycosis,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
zinc,mucormycosis,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
zinc,mucormycosis,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
zinc,mucormycosis,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
zinc,mucormycosis,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
zinc,mucormycosis,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
zinc,mucormycosis,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
zinc,mucormycosis,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
zinc,mucormycosis,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"Some clinical and epidemiological studies associated the usage of zinc supplements with the occurrence of COVID-19 associated mucormycosis, but experimental evidence remains limited.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,Rhizopus arrhizus,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
zinc,mucormycosis,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
zinc,Rhizopus arrhizus,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
zinc,mucormycosis,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
zinc,mucormycosis,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
zinc,mucormycosis,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,Rhizopus arrhizus,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
zinc,Rhizopus arrhizus,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
zinc,mucormycosis,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
zinc,mucormycosis,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
zinc,mucormycosis,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
Rhizopus arrhizus,mucormycosis,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
Rhizopus arrhizus,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
Rhizopus arrhizus,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
Rhizopus arrhizus,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
Rhizopus arrhizus,mucormycosis,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
Rhizopus arrhizus,mucormycosis,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
Rhizopus arrhizus,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
Rhizopus arrhizus,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
zinc,mucormycosis,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
zinc,mucormycosis,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
zinc,mucormycosis,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
zinc,mucormycosis,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
zinc,mucormycosis,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
zinc,mucormycosis,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"This study aimed to elucidate the impact of zinc enrichment on Rhizopus arrhizus, the predominant causative agent of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985
zinc,hydrogen peroxide,unknown,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985
zinc,sodium chloride,unknown,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985
zinc,hydrogen peroxide,unknown,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985
zinc,sodium chloride,unknown,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985
hydrogen peroxide,sodium chloride,unknown,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985
hydrogen peroxide,zinc,unknown,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985
hydrogen peroxide,zinc,unknown,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985
hydrogen peroxide,zinc,unknown,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985
hydrogen peroxide,zinc,unknown,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985
hydrogen peroxide,zinc,unknown,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985
sodium chloride,zinc,unknown,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985
sodium chloride,zinc,unknown,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985
sodium chloride,zinc,unknown,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985
sodium chloride,zinc,unknown,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985
sodium chloride,zinc,unknown,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The effect of zinc supplementation (5 to 150 {micro}M) on fungal growth, metabolic activity, antifungal susceptibility and biofilm formation, along with cell-wall (Congo red), oxidative (hydrogen peroxide) and osmotic (sodium chloride) stress was evaluated in RPMI-1640.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"Exposure to zinc enhanced the metabolic activity, and partly alleviated the cell-wall and oxidative stress.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"Exposure to zinc enhanced the metabolic activity, and partly alleviated the cell-wall and oxidative stress.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"Exposure to zinc enhanced the metabolic activity, and partly alleviated the cell-wall and oxidative stress.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"Exposure to zinc enhanced the metabolic activity, and partly alleviated the cell-wall and oxidative stress.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"Exposure to zinc enhanced the metabolic activity, and partly alleviated the cell-wall and oxidative stress.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"Exposure to zinc enhanced the metabolic activity, and partly alleviated the cell-wall and oxidative stress.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"Exposure to zinc enhanced the metabolic activity, and partly alleviated the cell-wall and oxidative stress.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"Exposure to zinc enhanced the metabolic activity, and partly alleviated the cell-wall and oxidative stress.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"Exposure to zinc enhanced the metabolic activity, and partly alleviated the cell-wall and oxidative stress.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"Exposure to zinc enhanced the metabolic activity, and partly alleviated the cell-wall and oxidative stress.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"Exposure to zinc enhanced the metabolic activity, and partly alleviated the cell-wall and oxidative stress.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"Exposure to zinc enhanced the metabolic activity, and partly alleviated the cell-wall and oxidative stress.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"Exposure to zinc enhanced the metabolic activity, and partly alleviated the cell-wall and oxidative stress.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"Exposure to zinc enhanced the metabolic activity, and partly alleviated the cell-wall and oxidative stress.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"Exposure to zinc enhanced the metabolic activity, and partly alleviated the cell-wall and oxidative stress.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"Exposure to zinc enhanced the metabolic activity, and partly alleviated the cell-wall and oxidative stress.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"Exposure to zinc enhanced the metabolic activity, and partly alleviated the cell-wall and oxidative stress.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"Exposure to zinc enhanced the metabolic activity, and partly alleviated the cell-wall and oxidative stress.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"Exposure to zinc enhanced the metabolic activity, and partly alleviated the cell-wall and oxidative stress.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"Exposure to zinc enhanced the metabolic activity, and partly alleviated the cell-wall and oxidative stress.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"Exposure to zinc enhanced the metabolic activity, and partly alleviated the cell-wall and oxidative stress.",10.1101/2025.10.13.681985
amphotericin B,posaconazole,unknown,Susceptibility to amphotericin B and posaconazole was unchanged.,10.1101/2025.10.13.681985
ergosterol,chitosan,unknown,"Zinc-supplemented cultures over-expressed multiple genes, notably those associated with respiratory electron transport chain, ergosterol biosynthesis, chitosan production, oxidative stress response, mucoricin, high-affinity iron permease, iron transport multi-copper oxidase and ferric-reductase-like protein.",10.1101/2025.10.13.681985
ergosterol,iron,unknown,"Zinc-supplemented cultures over-expressed multiple genes, notably those associated with respiratory electron transport chain, ergosterol biosynthesis, chitosan production, oxidative stress response, mucoricin, high-affinity iron permease, iron transport multi-copper oxidase and ferric-reductase-like protein.",10.1101/2025.10.13.681985
ergosterol,iron,unknown,"Zinc-supplemented cultures over-expressed multiple genes, notably those associated with respiratory electron transport chain, ergosterol biosynthesis, chitosan production, oxidative stress response, mucoricin, high-affinity iron permease, iron transport multi-copper oxidase and ferric-reductase-like protein.",10.1101/2025.10.13.681985
ergosterol,iron,unknown,"Zinc-supplemented cultures over-expressed multiple genes, notably those associated with respiratory electron transport chain, ergosterol biosynthesis, chitosan production, oxidative stress response, mucoricin, high-affinity iron permease, iron transport multi-copper oxidase and ferric-reductase-like protein.",10.1101/2025.10.13.681985
chitosan,iron,unknown,"Zinc-supplemented cultures over-expressed multiple genes, notably those associated with respiratory electron transport chain, ergosterol biosynthesis, chitosan production, oxidative stress response, mucoricin, high-affinity iron permease, iron transport multi-copper oxidase and ferric-reductase-like protein.",10.1101/2025.10.13.681985
chitosan,iron,unknown,"Zinc-supplemented cultures over-expressed multiple genes, notably those associated with respiratory electron transport chain, ergosterol biosynthesis, chitosan production, oxidative stress response, mucoricin, high-affinity iron permease, iron transport multi-copper oxidase and ferric-reductase-like protein.",10.1101/2025.10.13.681985
chitosan,iron,unknown,"Zinc-supplemented cultures over-expressed multiple genes, notably those associated with respiratory electron transport chain, ergosterol biosynthesis, chitosan production, oxidative stress response, mucoricin, high-affinity iron permease, iron transport multi-copper oxidase and ferric-reductase-like protein.",10.1101/2025.10.13.681985
iron,iron,unknown,"Zinc-supplemented cultures over-expressed multiple genes, notably those associated with respiratory electron transport chain, ergosterol biosynthesis, chitosan production, oxidative stress response, mucoricin, high-affinity iron permease, iron transport multi-copper oxidase and ferric-reductase-like protein.",10.1101/2025.10.13.681985
iron,iron,unknown,"Zinc-supplemented cultures over-expressed multiple genes, notably those associated with respiratory electron transport chain, ergosterol biosynthesis, chitosan production, oxidative stress response, mucoricin, high-affinity iron permease, iron transport multi-copper oxidase and ferric-reductase-like protein.",10.1101/2025.10.13.681985
iron,iron,unknown,"Zinc-supplemented cultures over-expressed multiple genes, notably those associated with respiratory electron transport chain, ergosterol biosynthesis, chitosan production, oxidative stress response, mucoricin, high-affinity iron permease, iron transport multi-copper oxidase and ferric-reductase-like protein.",10.1101/2025.10.13.681985
Candida albicans,Candida albicans,unknown,Zinc also augmented the growth/metabolism of several other Mucorales but not Aspergillus fumigatus and Candida albicans.,10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
zinc,mucormycosis,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
zinc,mucormycosis,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
zinc,mucormycosis,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
zinc,mucormycosis,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
zinc,mucormycosis,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
zinc,mucormycosis,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
zinc,mucormycosis,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
zinc,mucormycosis,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
zinc,mucormycosis,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
zinc,mucormycosis,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
zinc,mucormycosis,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
zinc,mucormycosis,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
zinc,mucormycosis,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The findings suggest that zinc supplementation supports mucoralean growth and enhances the expression of key virulence factors, implying that excessive intake of zinc supplements during COVID-19 pandemic likely contributed to the emergence of mucormycosis.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"Several risk factors were implicated in the emergence of COVID-19 associated mucormycosis (CAM), including inappropriate corticosteroid usage and COVID-19 associated glycemic imbalance.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"Several risk factors were implicated in the emergence of COVID-19 associated mucormycosis (CAM), including inappropriate corticosteroid usage and COVID-19 associated glycemic imbalance.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"Several risk factors were implicated in the emergence of COVID-19 associated mucormycosis (CAM), including inappropriate corticosteroid usage and COVID-19 associated glycemic imbalance.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"Several risk factors were implicated in the emergence of COVID-19 associated mucormycosis (CAM), including inappropriate corticosteroid usage and COVID-19 associated glycemic imbalance.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"Several risk factors were implicated in the emergence of COVID-19 associated mucormycosis (CAM), including inappropriate corticosteroid usage and COVID-19 associated glycemic imbalance.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"Several risk factors were implicated in the emergence of COVID-19 associated mucormycosis (CAM), including inappropriate corticosteroid usage and COVID-19 associated glycemic imbalance.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"Several risk factors were implicated in the emergence of COVID-19 associated mucormycosis (CAM), including inappropriate corticosteroid usage and COVID-19 associated glycemic imbalance.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"Several risk factors were implicated in the emergence of COVID-19 associated mucormycosis (CAM), including inappropriate corticosteroid usage and COVID-19 associated glycemic imbalance.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"Several risk factors were implicated in the emergence of COVID-19 associated mucormycosis (CAM), including inappropriate corticosteroid usage and COVID-19 associated glycemic imbalance.",10.1101/2025.10.13.681985
mucormycosis,mucormycosis,unknown,"Several risk factors were implicated in the emergence of COVID-19 associated mucormycosis (CAM), including inappropriate corticosteroid usage and COVID-19 associated glycemic imbalance.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The excessive intake of nutritional supplements, especially that of zinc, owing to self-medication and over-prescription, was also proposed as a plausible factor in the rise of CAM in many clinical/epidemiological studies.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The excessive intake of nutritional supplements, especially that of zinc, owing to self-medication and over-prescription, was also proposed as a plausible factor in the rise of CAM in many clinical/epidemiological studies.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The excessive intake of nutritional supplements, especially that of zinc, owing to self-medication and over-prescription, was also proposed as a plausible factor in the rise of CAM in many clinical/epidemiological studies.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The excessive intake of nutritional supplements, especially that of zinc, owing to self-medication and over-prescription, was also proposed as a plausible factor in the rise of CAM in many clinical/epidemiological studies.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The excessive intake of nutritional supplements, especially that of zinc, owing to self-medication and over-prescription, was also proposed as a plausible factor in the rise of CAM in many clinical/epidemiological studies.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The excessive intake of nutritional supplements, especially that of zinc, owing to self-medication and over-prescription, was also proposed as a plausible factor in the rise of CAM in many clinical/epidemiological studies.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The excessive intake of nutritional supplements, especially that of zinc, owing to self-medication and over-prescription, was also proposed as a plausible factor in the rise of CAM in many clinical/epidemiological studies.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The excessive intake of nutritional supplements, especially that of zinc, owing to self-medication and over-prescription, was also proposed as a plausible factor in the rise of CAM in many clinical/epidemiological studies.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The excessive intake of nutritional supplements, especially that of zinc, owing to self-medication and over-prescription, was also proposed as a plausible factor in the rise of CAM in many clinical/epidemiological studies.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The excessive intake of nutritional supplements, especially that of zinc, owing to self-medication and over-prescription, was also proposed as a plausible factor in the rise of CAM in many clinical/epidemiological studies.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The excessive intake of nutritional supplements, especially that of zinc, owing to self-medication and over-prescription, was also proposed as a plausible factor in the rise of CAM in many clinical/epidemiological studies.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The excessive intake of nutritional supplements, especially that of zinc, owing to self-medication and over-prescription, was also proposed as a plausible factor in the rise of CAM in many clinical/epidemiological studies.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The excessive intake of nutritional supplements, especially that of zinc, owing to self-medication and over-prescription, was also proposed as a plausible factor in the rise of CAM in many clinical/epidemiological studies.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The excessive intake of nutritional supplements, especially that of zinc, owing to self-medication and over-prescription, was also proposed as a plausible factor in the rise of CAM in many clinical/epidemiological studies.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The excessive intake of nutritional supplements, especially that of zinc, owing to self-medication and over-prescription, was also proposed as a plausible factor in the rise of CAM in many clinical/epidemiological studies.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The excessive intake of nutritional supplements, especially that of zinc, owing to self-medication and over-prescription, was also proposed as a plausible factor in the rise of CAM in many clinical/epidemiological studies.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The excessive intake of nutritional supplements, especially that of zinc, owing to self-medication and over-prescription, was also proposed as a plausible factor in the rise of CAM in many clinical/epidemiological studies.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The excessive intake of nutritional supplements, especially that of zinc, owing to self-medication and over-prescription, was also proposed as a plausible factor in the rise of CAM in many clinical/epidemiological studies.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The excessive intake of nutritional supplements, especially that of zinc, owing to self-medication and over-prescription, was also proposed as a plausible factor in the rise of CAM in many clinical/epidemiological studies.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The excessive intake of nutritional supplements, especially that of zinc, owing to self-medication and over-prescription, was also proposed as a plausible factor in the rise of CAM in many clinical/epidemiological studies.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The excessive intake of nutritional supplements, especially that of zinc, owing to self-medication and over-prescription, was also proposed as a plausible factor in the rise of CAM in many clinical/epidemiological studies.",10.1101/2025.10.13.681985
zinc,zinc,unknown,This study experimentally evaluated the potential impact of zinc enrichment on pathogenic Mucorales.,10.1101/2025.10.13.681985
zinc,zinc,unknown,This study experimentally evaluated the potential impact of zinc enrichment on pathogenic Mucorales.,10.1101/2025.10.13.681985
zinc,zinc,unknown,This study experimentally evaluated the potential impact of zinc enrichment on pathogenic Mucorales.,10.1101/2025.10.13.681985
zinc,zinc,unknown,This study experimentally evaluated the potential impact of zinc enrichment on pathogenic Mucorales.,10.1101/2025.10.13.681985
zinc,zinc,unknown,This study experimentally evaluated the potential impact of zinc enrichment on pathogenic Mucorales.,10.1101/2025.10.13.681985
zinc,zinc,unknown,This study experimentally evaluated the potential impact of zinc enrichment on pathogenic Mucorales.,10.1101/2025.10.13.681985
zinc,zinc,unknown,This study experimentally evaluated the potential impact of zinc enrichment on pathogenic Mucorales.,10.1101/2025.10.13.681985
zinc,zinc,unknown,This study experimentally evaluated the potential impact of zinc enrichment on pathogenic Mucorales.,10.1101/2025.10.13.681985
zinc,zinc,unknown,This study experimentally evaluated the potential impact of zinc enrichment on pathogenic Mucorales.,10.1101/2025.10.13.681985
zinc,zinc,unknown,This study experimentally evaluated the potential impact of zinc enrichment on pathogenic Mucorales.,10.1101/2025.10.13.681985
zinc,zinc,unknown,This study experimentally evaluated the potential impact of zinc enrichment on pathogenic Mucorales.,10.1101/2025.10.13.681985
zinc,zinc,unknown,This study experimentally evaluated the potential impact of zinc enrichment on pathogenic Mucorales.,10.1101/2025.10.13.681985
zinc,zinc,unknown,This study experimentally evaluated the potential impact of zinc enrichment on pathogenic Mucorales.,10.1101/2025.10.13.681985
zinc,zinc,unknown,This study experimentally evaluated the potential impact of zinc enrichment on pathogenic Mucorales.,10.1101/2025.10.13.681985
zinc,zinc,unknown,This study experimentally evaluated the potential impact of zinc enrichment on pathogenic Mucorales.,10.1101/2025.10.13.681985
zinc,zinc,unknown,This study experimentally evaluated the potential impact of zinc enrichment on pathogenic Mucorales.,10.1101/2025.10.13.681985
zinc,zinc,unknown,This study experimentally evaluated the potential impact of zinc enrichment on pathogenic Mucorales.,10.1101/2025.10.13.681985
zinc,zinc,unknown,This study experimentally evaluated the potential impact of zinc enrichment on pathogenic Mucorales.,10.1101/2025.10.13.681985
zinc,zinc,unknown,This study experimentally evaluated the potential impact of zinc enrichment on pathogenic Mucorales.,10.1101/2025.10.13.681985
zinc,zinc,unknown,This study experimentally evaluated the potential impact of zinc enrichment on pathogenic Mucorales.,10.1101/2025.10.13.681985
zinc,zinc,unknown,This study experimentally evaluated the potential impact of zinc enrichment on pathogenic Mucorales.,10.1101/2025.10.13.681985
zinc,zinc,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
zinc,Rhizopus arrhizus,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
zinc,iron,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
zinc,iron,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
zinc,iron,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
zinc,Rhizopus arrhizus,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
zinc,iron,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
zinc,iron,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
zinc,iron,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
Rhizopus arrhizus,zinc,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
Rhizopus arrhizus,iron,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
Rhizopus arrhizus,iron,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
Rhizopus arrhizus,zinc,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
Rhizopus arrhizus,zinc,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
Rhizopus arrhizus,zinc,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
Rhizopus arrhizus,iron,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
Rhizopus arrhizus,zinc,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
zinc,iron,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
zinc,iron,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
zinc,iron,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
iron,iron,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
iron,zinc,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
iron,zinc,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
iron,zinc,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
iron,iron,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
iron,zinc,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
iron,zinc,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
iron,zinc,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
iron,zinc,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
iron,iron,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
iron,zinc,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
zinc,iron,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
zinc,iron,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
zinc,iron,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
iron,zinc,unknown,"The work demonstrates that zinc supplementation supports Rhizopus arrhizus growth, metabolism and stress response, and enhances the expression of key virulence factors, including mucoricin and iron transporters.",10.1101/2025.10.13.681985
Candida albicans,Candida albicans,unknown,"Notably, the augmentation was specifically observed in pathogenic Mucorales but not Aspergillus fumigatus and Candida albicans.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The work provides experimental evidence for the potential association of zinc over-availability with the occurrence of CAM, and strengthens evidence-based therapeutic practices in clinical settings.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The work provides experimental evidence for the potential association of zinc over-availability with the occurrence of CAM, and strengthens evidence-based therapeutic practices in clinical settings.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The work provides experimental evidence for the potential association of zinc over-availability with the occurrence of CAM, and strengthens evidence-based therapeutic practices in clinical settings.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The work provides experimental evidence for the potential association of zinc over-availability with the occurrence of CAM, and strengthens evidence-based therapeutic practices in clinical settings.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The work provides experimental evidence for the potential association of zinc over-availability with the occurrence of CAM, and strengthens evidence-based therapeutic practices in clinical settings.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The work provides experimental evidence for the potential association of zinc over-availability with the occurrence of CAM, and strengthens evidence-based therapeutic practices in clinical settings.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The work provides experimental evidence for the potential association of zinc over-availability with the occurrence of CAM, and strengthens evidence-based therapeutic practices in clinical settings.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The work provides experimental evidence for the potential association of zinc over-availability with the occurrence of CAM, and strengthens evidence-based therapeutic practices in clinical settings.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The work provides experimental evidence for the potential association of zinc over-availability with the occurrence of CAM, and strengthens evidence-based therapeutic practices in clinical settings.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The work provides experimental evidence for the potential association of zinc over-availability with the occurrence of CAM, and strengthens evidence-based therapeutic practices in clinical settings.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The work provides experimental evidence for the potential association of zinc over-availability with the occurrence of CAM, and strengthens evidence-based therapeutic practices in clinical settings.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The work provides experimental evidence for the potential association of zinc over-availability with the occurrence of CAM, and strengthens evidence-based therapeutic practices in clinical settings.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The work provides experimental evidence for the potential association of zinc over-availability with the occurrence of CAM, and strengthens evidence-based therapeutic practices in clinical settings.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The work provides experimental evidence for the potential association of zinc over-availability with the occurrence of CAM, and strengthens evidence-based therapeutic practices in clinical settings.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The work provides experimental evidence for the potential association of zinc over-availability with the occurrence of CAM, and strengthens evidence-based therapeutic practices in clinical settings.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The work provides experimental evidence for the potential association of zinc over-availability with the occurrence of CAM, and strengthens evidence-based therapeutic practices in clinical settings.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The work provides experimental evidence for the potential association of zinc over-availability with the occurrence of CAM, and strengthens evidence-based therapeutic practices in clinical settings.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The work provides experimental evidence for the potential association of zinc over-availability with the occurrence of CAM, and strengthens evidence-based therapeutic practices in clinical settings.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The work provides experimental evidence for the potential association of zinc over-availability with the occurrence of CAM, and strengthens evidence-based therapeutic practices in clinical settings.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The work provides experimental evidence for the potential association of zinc over-availability with the occurrence of CAM, and strengthens evidence-based therapeutic practices in clinical settings.",10.1101/2025.10.13.681985
zinc,zinc,unknown,"The work provides experimental evidence for the potential association of zinc over-availability with the occurrence of CAM, and strengthens evidence-based therapeutic practices in clinical settings.",10.1101/2025.10.13.681985
coronavirus infection,infection,unknown,"Here, we report that coronavirus infection causes cytoplasmic poly(A)-binding protein (PABPC) activity to become limiting, which preferentially destabilizes short-tailed host mRNAs, occurring before the action of virally encoded mRNA-decay factor nsp1.",10.1101/2025.10.09.680815
coronavirus infection,coronavirus infection,unknown,"Here, we report that coronavirus infection causes cytoplasmic poly(A)-binding protein (PABPC) activity to become limiting, which preferentially destabilizes short-tailed host mRNAs, occurring before the action of virally encoded mRNA-decay factor nsp1.",10.1101/2025.10.09.680815
infection,coronavirus infection,unknown,"Here, we report that coronavirus infection causes cytoplasmic poly(A)-binding protein (PABPC) activity to become limiting, which preferentially destabilizes short-tailed host mRNAs, occurring before the action of virally encoded mRNA-decay factor nsp1.",10.1101/2025.10.09.680815
coronavirus infection,infection,unknown,"HighlightsO_LIPABPC1 becomes limiting during coronavirus infection C_LIO_LILimiting PABPC1 promotes decay of short-tailed host mRNAs--independently of nsp1 C_LIO_LIThe tail lengths of coronaviral mRNAs are extended during their synthesis in DMVs C_LIO_LIViral tails are capped by PABPC1 and CSDE1, which protects against deadenylation C_LI",10.1101/2025.10.09.680815
coronavirus infection,coronavirus infection,unknown,"HighlightsO_LIPABPC1 becomes limiting during coronavirus infection C_LIO_LILimiting PABPC1 promotes decay of short-tailed host mRNAs--independently of nsp1 C_LIO_LIThe tail lengths of coronaviral mRNAs are extended during their synthesis in DMVs C_LIO_LIViral tails are capped by PABPC1 and CSDE1, which protects against deadenylation C_LI",10.1101/2025.10.09.680815
infection,coronavirus infection,unknown,"HighlightsO_LIPABPC1 becomes limiting during coronavirus infection C_LIO_LILimiting PABPC1 promotes decay of short-tailed host mRNAs--independently of nsp1 C_LIO_LIThe tail lengths of coronaviral mRNAs are extended during their synthesis in DMVs C_LIO_LIViral tails are capped by PABPC1 and CSDE1, which protects against deadenylation C_LI",10.1101/2025.10.09.680815
upper respiratory tract,infection,unknown,"The upper respiratory tract (URT) represents the primary access point for respiratory viruses, where initial host infection occurs.",10.1101/2025.10.09.681417
upper respiratory tract,infection,unknown,"The upper respiratory tract (URT) represents the primary access point for respiratory viruses, where initial host infection occurs.",10.1101/2025.10.09.681417
upper respiratory tract,infection,unknown,"The upper respiratory tract (URT) represents the primary access point for respiratory viruses, where initial host infection occurs.",10.1101/2025.10.09.681417
infection,infection,unknown,"The upper respiratory tract (URT) represents the primary access point for respiratory viruses, where initial host infection occurs.",10.1101/2025.10.09.681417
infection,infection,unknown,"The upper respiratory tract (URT) represents the primary access point for respiratory viruses, where initial host infection occurs.",10.1101/2025.10.09.681417
infection,infection,unknown,"The upper respiratory tract (URT) represents the primary access point for respiratory viruses, where initial host infection occurs.",10.1101/2025.10.09.681417
infection,infection,unknown,"Vaccine-mediated URT mucosal memory responses can control infection, prevent transmission and limit viral evolution.",10.1101/2025.10.09.681417
infection,infection,unknown,"Vaccine-mediated URT mucosal memory responses can control infection, prevent transmission and limit viral evolution.",10.1101/2025.10.09.681417
infection,infection,unknown,"Vaccine-mediated URT mucosal memory responses can control infection, prevent transmission and limit viral evolution.",10.1101/2025.10.09.681417
infection,infection,unknown,"However, vaccines against respiratory viruses predominantly have systemic administration routes that elicit strong responses in the circulation to prevent severe respiratory disease, but do not effectively block infection and onward community transmission.",10.1101/2025.10.09.681417
infection,respiratory disease,unknown,"However, vaccines against respiratory viruses predominantly have systemic administration routes that elicit strong responses in the circulation to prevent severe respiratory disease, but do not effectively block infection and onward community transmission.",10.1101/2025.10.09.681417
infection,infection,unknown,"However, vaccines against respiratory viruses predominantly have systemic administration routes that elicit strong responses in the circulation to prevent severe respiratory disease, but do not effectively block infection and onward community transmission.",10.1101/2025.10.09.681417
infection,respiratory disease,unknown,"However, vaccines against respiratory viruses predominantly have systemic administration routes that elicit strong responses in the circulation to prevent severe respiratory disease, but do not effectively block infection and onward community transmission.",10.1101/2025.10.09.681417
infection,infection,unknown,"However, vaccines against respiratory viruses predominantly have systemic administration routes that elicit strong responses in the circulation to prevent severe respiratory disease, but do not effectively block infection and onward community transmission.",10.1101/2025.10.09.681417
respiratory disease,infection,unknown,"However, vaccines against respiratory viruses predominantly have systemic administration routes that elicit strong responses in the circulation to prevent severe respiratory disease, but do not effectively block infection and onward community transmission.",10.1101/2025.10.09.681417
methacholine,methacholine,unknown,"Secondary endpoints were changes in SARS-CoV-2 S1-specific IgG in serum and bronchoalveolar lavage; exploratory endpoints included changes in S1-specific IgA in serum and bronchoalveolar lavage, and methacholine responsiveness.",10.1101/2025.10.07.25337492
cough,headache,unknown,"Over 28 days, mild or moderate adverse events occurred in 87% of participants, predominantly cough, headache, and fatigue, all resolved.",10.1101/2025.10.07.25337492
cough,fatigue,unknown,"Over 28 days, mild or moderate adverse events occurred in 87% of participants, predominantly cough, headache, and fatigue, all resolved.",10.1101/2025.10.07.25337492
headache,fatigue,unknown,"Over 28 days, mild or moderate adverse events occurred in 87% of participants, predominantly cough, headache, and fatigue, all resolved.",10.1101/2025.10.07.25337492
methacholine,methacholine,unknown,"Pulmonary function and methacholine responsiveness were stable, except for one transient 20% decrease in FEV1 on Day 14 that normalized subsequently.",10.1101/2025.10.07.25337492
cancer,HPV-associated cancer,unknown,"Focusing on Iowa, a state with the fastest rising incidence of HPV-associated cancer, we evaluated if county-level COVID-19 vaccination rates corresponded to county-level changes in rural-urban HPV vaccination completion trends.",10.1101/2025.10.07.25337497
PD,PK,unknown,"Participants were monitored for 43 weeks to evaluate safety, pharmacokinetics (PK), and pharmacodynamics (PD; serum live virus neutralization).",10.1101/2025.10.07.25337449
Respiratory Syndrome,coronavirus disease 2019,unknown,Ensitrelvir is an antiviral drug that specifically targets the main protease (Mpro) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has been approved for the treatment of coronavirus disease 2019 (COVID-19) due to the conservation of its target protein which is essential in the viral lifecycle.,10.1101/2025.09.30.679586
{Delta}3a7b-Nluc,{Delta}3a7b-Nluc,unknown,"Here, we utilized a luminescent attenuated SARS-CoV-2 ({Delta}3a7b-Nluc WT) to safely identify ensitrelvir drug-resistant mutants (DRM-E) without the need of using virulent forms of SARS-CoV-2.",10.1101/2025.09.30.679586
{Delta}3a7b-Nluc,{Delta}3a7b-Nluc,unknown,The contribution of G23del was confirmed by generating a recombinant luminescent attenuated SARS-CoV-2 containing G23del in the non-structural protein 5 (NSP5) gene ({Delta}3a7b-Nluc G23del).,10.1101/2025.09.30.679586
{Delta}3a7b-Nluc,{Delta}3a7b-Nluc,unknown,{Delta}3a7b-Nluc G23del exhibited significant resistance to ensitrelvir in both cultured cells an in K18 hACE2 transgenic mice.,10.1101/2025.09.30.679586
"nirmatrelvir or remdesivir, suggesting the feasibility of treating",infections,unknown,"Positively, G23del in Mpro does not render SARS-CoV-2 resistant to nirmatrelvir or remdesivir, suggesting the feasibility of treating infections with SARS-CoV-2 containing G23del with these other approved antivirals.",10.1101/2025.09.30.679586
{Delta}3a7b-Nluc,{Delta}3a7b-Nluc,unknown,Our study addresses this by employing a luminescent attenuated virus platform ({Delta}3a7b-Nluc WT) to safely identify and characterize resistance mutations without the concern of using virulent forms of SARS-CoV-2.,10.1101/2025.09.30.679586
{Delta}3a7b-Nluc,{Delta}3a7b-Nluc,unknown,"Altogether, this study demonstrates the feasibility of using {Delta}3a7b-Nluc to safely identify and characterize drug resistant viruses without the biosafety concern of using virulent SARS-CoV-2 and advance the design of next-generation antiviral drugs.",10.1101/2025.09.30.679586
LTLAs,LTLAs,unknown,MethodsWe performed a DTW analysis on COVID-19 case time series stratified by the 380 Lower Tier Local Authorities (LTLAs) in the UK.,10.1101/2025.10.05.25337392
LTLAs,LTLAs,unknown,MethodsWe performed a DTW analysis on COVID-19 case time series stratified by the 380 Lower Tier Local Authorities (LTLAs) in the UK.,10.1101/2025.10.05.25337392
LTLAs,LTLAs,unknown,MethodsWe performed a DTW analysis on COVID-19 case time series stratified by the 380 Lower Tier Local Authorities (LTLAs) in the UK.,10.1101/2025.10.05.25337392
LTLAs,LTLAs,unknown,MethodsWe performed a DTW analysis on COVID-19 case time series stratified by the 380 Lower Tier Local Authorities (LTLAs) in the UK.,10.1101/2025.10.05.25337392
LTLAs,LTLAs,unknown,MethodsWe performed a DTW analysis on COVID-19 case time series stratified by the 380 Lower Tier Local Authorities (LTLAs) in the UK.,10.1101/2025.10.05.25337392
LTLAs,LTLAs,unknown,MethodsWe performed a DTW analysis on COVID-19 case time series stratified by the 380 Lower Tier Local Authorities (LTLAs) in the UK.,10.1101/2025.10.05.25337392
LTLAs,LTLAs,unknown,"ResultsOur clustering analysis found that case time series for LTLAs of Wales, Scotland, Northern Ireland and England were closely related to LTLAs within the same nation.",10.1101/2025.10.05.25337392
LTLAs,LTLAs,unknown,"ResultsOur clustering analysis found that case time series for LTLAs of Wales, Scotland, Northern Ireland and England were closely related to LTLAs within the same nation.",10.1101/2025.10.05.25337392
LTLAs,LTLAs,unknown,"ResultsOur clustering analysis found that case time series for LTLAs of Wales, Scotland, Northern Ireland and England were closely related to LTLAs within the same nation.",10.1101/2025.10.05.25337392
LTLAs,LTLAs,unknown,"ResultsOur clustering analysis found that case time series for LTLAs of Wales, Scotland, Northern Ireland and England were closely related to LTLAs within the same nation.",10.1101/2025.10.05.25337392
LTLAs,LTLAs,unknown,"ResultsOur clustering analysis found that case time series for LTLAs of Wales, Scotland, Northern Ireland and England were closely related to LTLAs within the same nation.",10.1101/2025.10.05.25337392
LTLAs,LTLAs,unknown,"ResultsOur clustering analysis found that case time series for LTLAs of Wales, Scotland, Northern Ireland and England were closely related to LTLAs within the same nation.",10.1101/2025.10.05.25337392
LTLAs,LTLAs,unknown,We identified groups of LTLAs in England with highly similar trends in case time series; these groups of LTLAs were geographically clustered despite the methodology not using any geographic information as input.,10.1101/2025.10.05.25337392
LTLAs,LTLAs,unknown,We identified groups of LTLAs in England with highly similar trends in case time series; these groups of LTLAs were geographically clustered despite the methodology not using any geographic information as input.,10.1101/2025.10.05.25337392
LTLAs,LTLAs,unknown,We identified groups of LTLAs in England with highly similar trends in case time series; these groups of LTLAs were geographically clustered despite the methodology not using any geographic information as input.,10.1101/2025.10.05.25337392
LTLAs,LTLAs,unknown,We identified groups of LTLAs in England with highly similar trends in case time series; these groups of LTLAs were geographically clustered despite the methodology not using any geographic information as input.,10.1101/2025.10.05.25337392
LTLAs,LTLAs,unknown,We identified groups of LTLAs in England with highly similar trends in case time series; these groups of LTLAs were geographically clustered despite the methodology not using any geographic information as input.,10.1101/2025.10.05.25337392
LTLAs,LTLAs,unknown,We identified groups of LTLAs in England with highly similar trends in case time series; these groups of LTLAs were geographically clustered despite the methodology not using any geographic information as input.,10.1101/2025.10.05.25337392
LTLAs,LTLAs,unknown,"The lead-lag time analysis in England showed that LTLAs in southeast England, the Manchester area, and in London each led the Alpha, Delta, and Omicron BA.1 epidemic waves respectively.",10.1101/2025.10.05.25337392
LTLAs,LTLAs,unknown,"The lead-lag time analysis in England showed that LTLAs in southeast England, the Manchester area, and in London each led the Alpha, Delta, and Omicron BA.1 epidemic waves respectively.",10.1101/2025.10.05.25337392
LTLAs,LTLAs,unknown,"The lead-lag time analysis in England showed that LTLAs in southeast England, the Manchester area, and in London each led the Alpha, Delta, and Omicron BA.1 epidemic waves respectively.",10.1101/2025.10.05.25337392
LTLAs,LTLAs,unknown,"The lead-lag time analysis in England showed that LTLAs in southeast England, the Manchester area, and in London each led the Alpha, Delta, and Omicron BA.1 epidemic waves respectively.",10.1101/2025.10.05.25337392
LTLAs,LTLAs,unknown,"The lead-lag time analysis in England showed that LTLAs in southeast England, the Manchester area, and in London each led the Alpha, Delta, and Omicron BA.1 epidemic waves respectively.",10.1101/2025.10.05.25337392
LTLAs,LTLAs,unknown,"The lead-lag time analysis in England showed that LTLAs in southeast England, the Manchester area, and in London each led the Alpha, Delta, and Omicron BA.1 epidemic waves respectively.",10.1101/2025.10.05.25337392
nontuberculous mycobacterial,NTM,unknown,"BackgroundThe incidence of nontuberculous mycobacterial (NTM) diseases is increasing globally, with risk factors remaining poorly understood.",10.1101/2025.10.02.25337223
nontuberculous mycobacterial,NTM,unknown,"BackgroundThe incidence of nontuberculous mycobacterial (NTM) diseases is increasing globally, with risk factors remaining poorly understood.",10.1101/2025.10.02.25337223
nontuberculous mycobacterial,NTM,unknown,"BackgroundThe incidence of nontuberculous mycobacterial (NTM) diseases is increasing globally, with risk factors remaining poorly understood.",10.1101/2025.10.02.25337223
NTM,NTM,unknown,"BackgroundThe incidence of nontuberculous mycobacterial (NTM) diseases is increasing globally, with risk factors remaining poorly understood.",10.1101/2025.10.02.25337223
NTM,NTM,unknown,"BackgroundThe incidence of nontuberculous mycobacterial (NTM) diseases is increasing globally, with risk factors remaining poorly understood.",10.1101/2025.10.02.25337223
NTM,NTM,unknown,"BackgroundThe incidence of nontuberculous mycobacterial (NTM) diseases is increasing globally, with risk factors remaining poorly understood.",10.1101/2025.10.02.25337223
NTM,NTM,unknown,COVID-19 may alter respiratory tract conditions affecting NTM colonization and infection patterns.,10.1101/2025.10.02.25337223
NTM,infection,unknown,COVID-19 may alter respiratory tract conditions affecting NTM colonization and infection patterns.,10.1101/2025.10.02.25337223
NTM,NTM,unknown,COVID-19 may alter respiratory tract conditions affecting NTM colonization and infection patterns.,10.1101/2025.10.02.25337223
NTM,infection,unknown,COVID-19 may alter respiratory tract conditions affecting NTM colonization and infection patterns.,10.1101/2025.10.02.25337223
NTM,NTM,unknown,COVID-19 may alter respiratory tract conditions affecting NTM colonization and infection patterns.,10.1101/2025.10.02.25337223
infection,NTM,unknown,COVID-19 may alter respiratory tract conditions affecting NTM colonization and infection patterns.,10.1101/2025.10.02.25337223
NTM,NTM,unknown,ObjectiveTo evaluate species diversity of NTM isolated from patients with NTM-associated diseases with and without a history of COVID-19.,10.1101/2025.10.02.25337223
NTM,NTM,unknown,ObjectiveTo evaluate species diversity of NTM isolated from patients with NTM-associated diseases with and without a history of COVID-19.,10.1101/2025.10.02.25337223
NTM,NTM-associated diseases,unknown,ObjectiveTo evaluate species diversity of NTM isolated from patients with NTM-associated diseases with and without a history of COVID-19.,10.1101/2025.10.02.25337223
NTM,NTM-associated diseases,unknown,ObjectiveTo evaluate species diversity of NTM isolated from patients with NTM-associated diseases with and without a history of COVID-19.,10.1101/2025.10.02.25337223
NTM,NTM,unknown,ObjectiveTo evaluate species diversity of NTM isolated from patients with NTM-associated diseases with and without a history of COVID-19.,10.1101/2025.10.02.25337223
NTM,NTM-associated diseases,unknown,ObjectiveTo evaluate species diversity of NTM isolated from patients with NTM-associated diseases with and without a history of COVID-19.,10.1101/2025.10.02.25337223
NTM,NTM-associated diseases,unknown,ObjectiveTo evaluate species diversity of NTM isolated from patients with NTM-associated diseases with and without a history of COVID-19.,10.1101/2025.10.02.25337223
NTM,NTM-associated diseases,unknown,ObjectiveTo evaluate species diversity of NTM isolated from patients with NTM-associated diseases with and without a history of COVID-19.,10.1101/2025.10.02.25337223
NTM,NTM-associated diseases,unknown,ObjectiveTo evaluate species diversity of NTM isolated from patients with NTM-associated diseases with and without a history of COVID-19.,10.1101/2025.10.02.25337223
NTM-associated diseases,NTM-associated diseases,unknown,ObjectiveTo evaluate species diversity of NTM isolated from patients with NTM-associated diseases with and without a history of COVID-19.,10.1101/2025.10.02.25337223
NTM,NTM,unknown,"MethodsWe analyzed 464 clinical NTM isolates from Russian patients stratified by COVID-19 status (COVID-19+, n=271; COVID-19-, n=193).",10.1101/2025.10.02.25337223
NTM,NTM,unknown,"MethodsWe analyzed 464 clinical NTM isolates from Russian patients stratified by COVID-19 status (COVID-19+, n=271; COVID-19-, n=193).",10.1101/2025.10.02.25337223
NTM,NTM,unknown,"MethodsWe analyzed 464 clinical NTM isolates from Russian patients stratified by COVID-19 status (COVID-19+, n=271; COVID-19-, n=193).",10.1101/2025.10.02.25337223
Mycobacterium avium,avium,unknown,"COVID-19 was associated with a significant 28% reduction in Mycobacterium avium complex (MAC) prevalence (94.8% vs 66.8%, p<0.05), primarily due to decreased M. avium isolation (80.3% vs 52.0%, p<0.05).",10.1101/2025.10.02.25337223
NTM,NTM,unknown,"Conversely, rare NTM species showed increased prevalence in COVID-19+ patients: M. kansasii complex (0% vs 8.1%, p<0.05), M. terrae complex (0% vs 3.3%, p<0.05), M. simiae complex (0.5% vs 7.0%, p<0.05), and unclassifiable species (2.6% vs 12.9%, p<0.05).",10.1101/2025.10.02.25337223
NTM,NTM,unknown,"Conversely, rare NTM species showed increased prevalence in COVID-19+ patients: M. kansasii complex (0% vs 8.1%, p<0.05), M. terrae complex (0% vs 3.3%, p<0.05), M. simiae complex (0.5% vs 7.0%, p<0.05), and unclassifiable species (2.6% vs 12.9%, p<0.05).",10.1101/2025.10.02.25337223
NTM,terrae,unknown,"Conversely, rare NTM species showed increased prevalence in COVID-19+ patients: M. kansasii complex (0% vs 8.1%, p<0.05), M. terrae complex (0% vs 3.3%, p<0.05), M. simiae complex (0.5% vs 7.0%, p<0.05), and unclassifiable species (2.6% vs 12.9%, p<0.05).",10.1101/2025.10.02.25337223
NTM,NTM,unknown,"Conversely, rare NTM species showed increased prevalence in COVID-19+ patients: M. kansasii complex (0% vs 8.1%, p<0.05), M. terrae complex (0% vs 3.3%, p<0.05), M. simiae complex (0.5% vs 7.0%, p<0.05), and unclassifiable species (2.6% vs 12.9%, p<0.05).",10.1101/2025.10.02.25337223
NTM,terrae,unknown,"Conversely, rare NTM species showed increased prevalence in COVID-19+ patients: M. kansasii complex (0% vs 8.1%, p<0.05), M. terrae complex (0% vs 3.3%, p<0.05), M. simiae complex (0.5% vs 7.0%, p<0.05), and unclassifiable species (2.6% vs 12.9%, p<0.05).",10.1101/2025.10.02.25337223
NTM,terrae,unknown,"Conversely, rare NTM species showed increased prevalence in COVID-19+ patients: M. kansasii complex (0% vs 8.1%, p<0.05), M. terrae complex (0% vs 3.3%, p<0.05), M. simiae complex (0.5% vs 7.0%, p<0.05), and unclassifiable species (2.6% vs 12.9%, p<0.05).",10.1101/2025.10.02.25337223
NTM,NTM,unknown,"ConclusionsCOVID-19 significantly alters the NTM species spectrum in patients with NTM-associated diseases, with reduced MAC prevalence and increased detection of rare NTM species.",10.1101/2025.10.02.25337223
NTM,NTM,unknown,"ConclusionsCOVID-19 significantly alters the NTM species spectrum in patients with NTM-associated diseases, with reduced MAC prevalence and increased detection of rare NTM species.",10.1101/2025.10.02.25337223
NTM,NTM-associated diseases,unknown,"ConclusionsCOVID-19 significantly alters the NTM species spectrum in patients with NTM-associated diseases, with reduced MAC prevalence and increased detection of rare NTM species.",10.1101/2025.10.02.25337223
NTM,NTM-associated diseases,unknown,"ConclusionsCOVID-19 significantly alters the NTM species spectrum in patients with NTM-associated diseases, with reduced MAC prevalence and increased detection of rare NTM species.",10.1101/2025.10.02.25337223
NTM,NTM,unknown,"ConclusionsCOVID-19 significantly alters the NTM species spectrum in patients with NTM-associated diseases, with reduced MAC prevalence and increased detection of rare NTM species.",10.1101/2025.10.02.25337223
NTM,NTM-associated diseases,unknown,"ConclusionsCOVID-19 significantly alters the NTM species spectrum in patients with NTM-associated diseases, with reduced MAC prevalence and increased detection of rare NTM species.",10.1101/2025.10.02.25337223
NTM,NTM-associated diseases,unknown,"ConclusionsCOVID-19 significantly alters the NTM species spectrum in patients with NTM-associated diseases, with reduced MAC prevalence and increased detection of rare NTM species.",10.1101/2025.10.02.25337223
NTM,NTM-associated diseases,unknown,"ConclusionsCOVID-19 significantly alters the NTM species spectrum in patients with NTM-associated diseases, with reduced MAC prevalence and increased detection of rare NTM species.",10.1101/2025.10.02.25337223
NTM,NTM-associated diseases,unknown,"ConclusionsCOVID-19 significantly alters the NTM species spectrum in patients with NTM-associated diseases, with reduced MAC prevalence and increased detection of rare NTM species.",10.1101/2025.10.02.25337223
NTM-associated diseases,NTM-associated diseases,unknown,"ConclusionsCOVID-19 significantly alters the NTM species spectrum in patients with NTM-associated diseases, with reduced MAC prevalence and increased detection of rare NTM species.",10.1101/2025.10.02.25337223
infection,infection,unknown,"The ease with which emerging SARS-CoV-2 variants escape neutralizing antibodies limits protection afforded by a prior exposure, be it infection or vaccination.",10.1101/2025.10.03.679858
infection,infection,unknown,"Motivated by findings that plasma responses show increased neutralization breadth and potency with continued antigen exposure, we isolated monoclonal antibodies (mAbs) after a SARS-CoV-2 re-infection and compared them to those isolated one year prior, after the first breakthrough infection.",10.1101/2025.10.03.679858
infection,infection,unknown,"One mAb isolated after re-infection, C68.490, targets a conserved region in the receptor binding domain core and shows remarkable activity not only against SARS-CoV-2 variants, but also diverse sarbecoviruses from more distant clades present in animal reservoirs.",10.1101/2025.10.03.679858
Respiratory Syndrome,SARS,unknown,BackgroundThe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has continued to be a global health threat despite many interventions put with new variants noticed.,10.1101/2025.09.27.25336412
Respiratory Syndrome,SARS,unknown,BackgroundThe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has continued to be a global health threat despite many interventions put with new variants noticed.,10.1101/2025.09.27.25336412
SARS,SARS,unknown,BackgroundThe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has continued to be a global health threat despite many interventions put with new variants noticed.,10.1101/2025.09.27.25336412
SARS,SARS,unknown,There is scarce information on SARS-CoV-2 predisposing factors in relation to the proximate-determinant framework in Zambia.,10.1101/2025.09.27.25336412
SARS,SARS,unknown,This study aimed to determine epidemiological and cluster predictions on prevention strategies of SARS-CoV-2 cases in Zambia 2019-2024 in rural and urban settings.,10.1101/2025.09.27.25336412
SARS,SARS,unknown,The target population were all the reported and recorded SARS CoV-2 cases above 15 years and all active cases.,10.1101/2025.09.27.25336412
SARS,SARS,unknown,Results624 participated in this study with 528 cases having had tested or confirmed records of SARS CoV-2 test status with mean age 32 (SD10.3).,10.1101/2025.09.27.25336412
infection,infection,unknown,"Persons observed at risk of severe cases of infection were; elderly males above 49 years (cOR=2.13, 95% CI: 1.16-3.89, p<0.014), and those who had other co-morbidities (43%).",10.1101/2025.09.27.25336412
SARS,SARS,unknown,Participants aged 49 years and above and had experienced symptoms of SARS-CoV-2 had a significant effect on testing positive.,10.1101/2025.09.27.25336412
SARS,SARS,unknown,"ConclusionMajority of the population were knowledgeable about the causes, transmission risks and the SARS CoV-2 prevention guidelines.",10.1101/2025.09.27.25336412
SARS,SARS,unknown,Failure to adhere to the stipulated SARS CoV-2 prevention guidelines accounted for most of the increases transmission rate among the sub-populations.,10.1101/2025.09.27.25336412
infection,infection,unknown,Adults above 49 years with other co-commodities and not vaccinated were the most affected with the infection,10.1101/2025.09.27.25336412
TACO,TACO,unknown,"We present TACO (TabPFN Augmented Causal Outcomes), a framework that uniquely combines causal inference with foundation models for presymptomatic Long COVID detection.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"We present TACO (TabPFN Augmented Causal Outcomes), a framework that uniquely combines causal inference with foundation models for presymptomatic Long COVID detection.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"We present TACO (TabPFN Augmented Causal Outcomes), a framework that uniquely combines causal inference with foundation models for presymptomatic Long COVID detection.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"We present TACO (TabPFN Augmented Causal Outcomes), a framework that uniquely combines causal inference with foundation models for presymptomatic Long COVID detection.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"We present TACO (TabPFN Augmented Causal Outcomes), a framework that uniquely combines causal inference with foundation models for presymptomatic Long COVID detection.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"We present TACO (TabPFN Augmented Causal Outcomes), a framework that uniquely combines causal inference with foundation models for presymptomatic Long COVID detection.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"We present TACO (TabPFN Augmented Causal Outcomes), a framework that uniquely combines causal inference with foundation models for presymptomatic Long COVID detection.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"We present TACO (TabPFN Augmented Causal Outcomes), a framework that uniquely combines causal inference with foundation models for presymptomatic Long COVID detection.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"We present TACO (TabPFN Augmented Causal Outcomes), a framework that uniquely combines causal inference with foundation models for presymptomatic Long COVID detection.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"We present TACO (TabPFN Augmented Causal Outcomes), a framework that uniquely combines causal inference with foundation models for presymptomatic Long COVID detection.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"TACO employs Differential Causal Effect (DCE) analysis to identify causally relevant genes, then utilizes TabPFN, a foundation model that does not require hyperparameter adjustment, to achieve consistent performance.",10.1101/2025.10.02.25337138
TACO,DCE,unknown,"TACO employs Differential Causal Effect (DCE) analysis to identify causally relevant genes, then utilizes TabPFN, a foundation model that does not require hyperparameter adjustment, to achieve consistent performance.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"TACO employs Differential Causal Effect (DCE) analysis to identify causally relevant genes, then utilizes TabPFN, a foundation model that does not require hyperparameter adjustment, to achieve consistent performance.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"TACO employs Differential Causal Effect (DCE) analysis to identify causally relevant genes, then utilizes TabPFN, a foundation model that does not require hyperparameter adjustment, to achieve consistent performance.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"TACO employs Differential Causal Effect (DCE) analysis to identify causally relevant genes, then utilizes TabPFN, a foundation model that does not require hyperparameter adjustment, to achieve consistent performance.",10.1101/2025.10.02.25337138
TACO,DCE,unknown,"TACO employs Differential Causal Effect (DCE) analysis to identify causally relevant genes, then utilizes TabPFN, a foundation model that does not require hyperparameter adjustment, to achieve consistent performance.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"TACO employs Differential Causal Effect (DCE) analysis to identify causally relevant genes, then utilizes TabPFN, a foundation model that does not require hyperparameter adjustment, to achieve consistent performance.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"TACO employs Differential Causal Effect (DCE) analysis to identify causally relevant genes, then utilizes TabPFN, a foundation model that does not require hyperparameter adjustment, to achieve consistent performance.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"TACO employs Differential Causal Effect (DCE) analysis to identify causally relevant genes, then utilizes TabPFN, a foundation model that does not require hyperparameter adjustment, to achieve consistent performance.",10.1101/2025.10.02.25337138
DCE,TACO,unknown,"TACO employs Differential Causal Effect (DCE) analysis to identify causally relevant genes, then utilizes TabPFN, a foundation model that does not require hyperparameter adjustment, to achieve consistent performance.",10.1101/2025.10.02.25337138
DCE,TACO,unknown,"TACO employs Differential Causal Effect (DCE) analysis to identify causally relevant genes, then utilizes TabPFN, a foundation model that does not require hyperparameter adjustment, to achieve consistent performance.",10.1101/2025.10.02.25337138
DCE,TACO,unknown,"TACO employs Differential Causal Effect (DCE) analysis to identify causally relevant genes, then utilizes TabPFN, a foundation model that does not require hyperparameter adjustment, to achieve consistent performance.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"TACO employs Differential Causal Effect (DCE) analysis to identify causally relevant genes, then utilizes TabPFN, a foundation model that does not require hyperparameter adjustment, to achieve consistent performance.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"TACO employs Differential Causal Effect (DCE) analysis to identify causally relevant genes, then utilizes TabPFN, a foundation model that does not require hyperparameter adjustment, to achieve consistent performance.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"TACO employs Differential Causal Effect (DCE) analysis to identify causally relevant genes, then utilizes TabPFN, a foundation model that does not require hyperparameter adjustment, to achieve consistent performance.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"In comprehensive benchmarking, TACO achieved superior precision using 18% fewer features than conventional approaches.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"In comprehensive benchmarking, TACO achieved superior precision using 18% fewer features than conventional approaches.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"In comprehensive benchmarking, TACO achieved superior precision using 18% fewer features than conventional approaches.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"In comprehensive benchmarking, TACO achieved superior precision using 18% fewer features than conventional approaches.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"In comprehensive benchmarking, TACO achieved superior precision using 18% fewer features than conventional approaches.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"In comprehensive benchmarking, TACO achieved superior precision using 18% fewer features than conventional approaches.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"In comprehensive benchmarking, TACO achieved superior precision using 18% fewer features than conventional approaches.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"In comprehensive benchmarking, TACO achieved superior precision using 18% fewer features than conventional approaches.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"In comprehensive benchmarking, TACO achieved superior precision using 18% fewer features than conventional approaches.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"In comprehensive benchmarking, TACO achieved superior precision using 18% fewer features than conventional approaches.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"Critically, TACO maintains consistent performance without any hyperparameter optimization, while benchmark models show variable results depending on the tuning.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"Critically, TACO maintains consistent performance without any hyperparameter optimization, while benchmark models show variable results depending on the tuning.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"Critically, TACO maintains consistent performance without any hyperparameter optimization, while benchmark models show variable results depending on the tuning.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"Critically, TACO maintains consistent performance without any hyperparameter optimization, while benchmark models show variable results depending on the tuning.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"Critically, TACO maintains consistent performance without any hyperparameter optimization, while benchmark models show variable results depending on the tuning.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"Critically, TACO maintains consistent performance without any hyperparameter optimization, while benchmark models show variable results depending on the tuning.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"Critically, TACO maintains consistent performance without any hyperparameter optimization, while benchmark models show variable results depending on the tuning.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"Critically, TACO maintains consistent performance without any hyperparameter optimization, while benchmark models show variable results depending on the tuning.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"Critically, TACO maintains consistent performance without any hyperparameter optimization, while benchmark models show variable results depending on the tuning.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"Critically, TACO maintains consistent performance without any hyperparameter optimization, while benchmark models show variable results depending on the tuning.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"By prioritizing causal mechanisms over statistical associations and eliminating the need for hyperparameter search, TACO offers a practical, interpretable solution for clinical deployment, transforming Long COVID management from reactive diagnosis to proactive prevention.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"By prioritizing causal mechanisms over statistical associations and eliminating the need for hyperparameter search, TACO offers a practical, interpretable solution for clinical deployment, transforming Long COVID management from reactive diagnosis to proactive prevention.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"By prioritizing causal mechanisms over statistical associations and eliminating the need for hyperparameter search, TACO offers a practical, interpretable solution for clinical deployment, transforming Long COVID management from reactive diagnosis to proactive prevention.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"By prioritizing causal mechanisms over statistical associations and eliminating the need for hyperparameter search, TACO offers a practical, interpretable solution for clinical deployment, transforming Long COVID management from reactive diagnosis to proactive prevention.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"By prioritizing causal mechanisms over statistical associations and eliminating the need for hyperparameter search, TACO offers a practical, interpretable solution for clinical deployment, transforming Long COVID management from reactive diagnosis to proactive prevention.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"By prioritizing causal mechanisms over statistical associations and eliminating the need for hyperparameter search, TACO offers a practical, interpretable solution for clinical deployment, transforming Long COVID management from reactive diagnosis to proactive prevention.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"By prioritizing causal mechanisms over statistical associations and eliminating the need for hyperparameter search, TACO offers a practical, interpretable solution for clinical deployment, transforming Long COVID management from reactive diagnosis to proactive prevention.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"By prioritizing causal mechanisms over statistical associations and eliminating the need for hyperparameter search, TACO offers a practical, interpretable solution for clinical deployment, transforming Long COVID management from reactive diagnosis to proactive prevention.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"By prioritizing causal mechanisms over statistical associations and eliminating the need for hyperparameter search, TACO offers a practical, interpretable solution for clinical deployment, transforming Long COVID management from reactive diagnosis to proactive prevention.",10.1101/2025.10.02.25337138
TACO,TACO,unknown,"By prioritizing causal mechanisms over statistical associations and eliminating the need for hyperparameter search, TACO offers a practical, interpretable solution for clinical deployment, transforming Long COVID management from reactive diagnosis to proactive prevention.",10.1101/2025.10.02.25337138
OC43,sHCoVs,unknown,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743
sHCoVs,OC43,unknown,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743
sHCoVs,OC43,unknown,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743
sHCoVs,OC43,unknown,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743
sHCoVs,OC43,unknown,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743
sHCoVs,OC43,unknown,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743
sHCoVs,OC43,unknown,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"B-cell responses towards seasonal human coronaviruses (sHCoVs), particularly OC43, impacted those towards SARS-CoV-2 due to immune imprinting in severe COVID-19 patients.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"Subsequently, we determined the OC43 neutralization potential of sera and monoclonal antibodies targeting different S domains.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"Subsequently, we determined the OC43 neutralization potential of sera and monoclonal antibodies targeting different S domains.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"Subsequently, we determined the OC43 neutralization potential of sera and monoclonal antibodies targeting different S domains.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"Subsequently, we determined the OC43 neutralization potential of sera and monoclonal antibodies targeting different S domains.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"Subsequently, we determined the OC43 neutralization potential of sera and monoclonal antibodies targeting different S domains.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"Subsequently, we determined the OC43 neutralization potential of sera and monoclonal antibodies targeting different S domains.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"Subsequently, we determined the OC43 neutralization potential of sera and monoclonal antibodies targeting different S domains.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"Subsequently, we determined the OC43 neutralization potential of sera and monoclonal antibodies targeting different S domains.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"Subsequently, we determined the OC43 neutralization potential of sera and monoclonal antibodies targeting different S domains.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"Subsequently, we determined the OC43 neutralization potential of sera and monoclonal antibodies targeting different S domains.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"Subsequently, we determined the OC43 neutralization potential of sera and monoclonal antibodies targeting different S domains.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"Subsequently, we determined the OC43 neutralization potential of sera and monoclonal antibodies targeting different S domains.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"Subsequently, we determined the OC43 neutralization potential of sera and monoclonal antibodies targeting different S domains.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"Subsequently, we determined the OC43 neutralization potential of sera and monoclonal antibodies targeting different S domains.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"Subsequently, we determined the OC43 neutralization potential of sera and monoclonal antibodies targeting different S domains.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"Subsequently, we determined the OC43 neutralization potential of sera and monoclonal antibodies targeting different S domains.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"Subsequently, we determined the OC43 neutralization potential of sera and monoclonal antibodies targeting different S domains.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"Subsequently, we determined the OC43 neutralization potential of sera and monoclonal antibodies targeting different S domains.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"Subsequently, we determined the OC43 neutralization potential of sera and monoclonal antibodies targeting different S domains.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"Subsequently, we determined the OC43 neutralization potential of sera and monoclonal antibodies targeting different S domains.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"Subsequently, we determined the OC43 neutralization potential of sera and monoclonal antibodies targeting different S domains.",10.1101/2025.09.28.25336743
OC43,sHCoVs,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
OC43,NL63,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
OC43,NL63,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
sHCoVs,OC43,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
sHCoVs,NL63,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
sHCoVs,OC43,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
sHCoVs,OC43,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
sHCoVs,OC43,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
sHCoVs,OC43,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
sHCoVs,OC43,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
sHCoVs,NL63,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
OC43,NL63,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
OC43,NL63,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
NL63,OC43,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
NL63,OC43,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
NL63,OC43,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
NL63,OC43,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
NL63,OC43,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
NL63,NL63,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
OC43,NL63,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
OC43,NL63,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
OC43,NL63,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
OC43,NL63,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
OC43,NL63,unknown,The SARS-CoV-2/sHCoVs cross-reactive clones accounted for higher NL63 S1- and OC43 S2-specific B-cell frequencies and matched higher serum antibody titers.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,"For OC43, the immunodominance of SARS-CoV-2/OC43 cross-reactive IgG B-cells resulted in a strong bias towards S2.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"For OC43, the immunodominance of SARS-CoV-2/OC43 cross-reactive IgG B-cells resulted in a strong bias towards S2.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"For OC43, the immunodominance of SARS-CoV-2/OC43 cross-reactive IgG B-cells resulted in a strong bias towards S2.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"For OC43, the immunodominance of SARS-CoV-2/OC43 cross-reactive IgG B-cells resulted in a strong bias towards S2.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"For OC43, the immunodominance of SARS-CoV-2/OC43 cross-reactive IgG B-cells resulted in a strong bias towards S2.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"For OC43, the immunodominance of SARS-CoV-2/OC43 cross-reactive IgG B-cells resulted in a strong bias towards S2.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"For OC43, the immunodominance of SARS-CoV-2/OC43 cross-reactive IgG B-cells resulted in a strong bias towards S2.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"For OC43, the immunodominance of SARS-CoV-2/OC43 cross-reactive IgG B-cells resulted in a strong bias towards S2.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"For OC43, the immunodominance of SARS-CoV-2/OC43 cross-reactive IgG B-cells resulted in a strong bias towards S2.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"For OC43, the immunodominance of SARS-CoV-2/OC43 cross-reactive IgG B-cells resulted in a strong bias towards S2.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"For OC43, the immunodominance of SARS-CoV-2/OC43 cross-reactive IgG B-cells resulted in a strong bias towards S2.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"For OC43, the immunodominance of SARS-CoV-2/OC43 cross-reactive IgG B-cells resulted in a strong bias towards S2.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"For OC43, the immunodominance of SARS-CoV-2/OC43 cross-reactive IgG B-cells resulted in a strong bias towards S2.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"For OC43, the immunodominance of SARS-CoV-2/OC43 cross-reactive IgG B-cells resulted in a strong bias towards S2.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"For OC43, the immunodominance of SARS-CoV-2/OC43 cross-reactive IgG B-cells resulted in a strong bias towards S2.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"For OC43, the immunodominance of SARS-CoV-2/OC43 cross-reactive IgG B-cells resulted in a strong bias towards S2.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"For OC43, the immunodominance of SARS-CoV-2/OC43 cross-reactive IgG B-cells resulted in a strong bias towards S2.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"For OC43, the immunodominance of SARS-CoV-2/OC43 cross-reactive IgG B-cells resulted in a strong bias towards S2.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"For OC43, the immunodominance of SARS-CoV-2/OC43 cross-reactive IgG B-cells resulted in a strong bias towards S2.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"For OC43, the immunodominance of SARS-CoV-2/OC43 cross-reactive IgG B-cells resulted in a strong bias towards S2.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"For OC43, the immunodominance of SARS-CoV-2/OC43 cross-reactive IgG B-cells resulted in a strong bias towards S2.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,Serum OC43 neutralization titers were higher in end-pandemic donors and correlated with OC43 S1 and S2-specific IgG titers and reactive B-cells frequencies.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,Serum OC43 neutralization titers were higher in end-pandemic donors and correlated with OC43 S1 and S2-specific IgG titers and reactive B-cells frequencies.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,Serum OC43 neutralization titers were higher in end-pandemic donors and correlated with OC43 S1 and S2-specific IgG titers and reactive B-cells frequencies.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,Serum OC43 neutralization titers were higher in end-pandemic donors and correlated with OC43 S1 and S2-specific IgG titers and reactive B-cells frequencies.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,Serum OC43 neutralization titers were higher in end-pandemic donors and correlated with OC43 S1 and S2-specific IgG titers and reactive B-cells frequencies.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,Serum OC43 neutralization titers were higher in end-pandemic donors and correlated with OC43 S1 and S2-specific IgG titers and reactive B-cells frequencies.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,Serum OC43 neutralization titers were higher in end-pandemic donors and correlated with OC43 S1 and S2-specific IgG titers and reactive B-cells frequencies.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,Serum OC43 neutralization titers were higher in end-pandemic donors and correlated with OC43 S1 and S2-specific IgG titers and reactive B-cells frequencies.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,Serum OC43 neutralization titers were higher in end-pandemic donors and correlated with OC43 S1 and S2-specific IgG titers and reactive B-cells frequencies.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,Serum OC43 neutralization titers were higher in end-pandemic donors and correlated with OC43 S1 and S2-specific IgG titers and reactive B-cells frequencies.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,Serum OC43 neutralization titers were higher in end-pandemic donors and correlated with OC43 S1 and S2-specific IgG titers and reactive B-cells frequencies.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,Serum OC43 neutralization titers were higher in end-pandemic donors and correlated with OC43 S1 and S2-specific IgG titers and reactive B-cells frequencies.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,Serum OC43 neutralization titers were higher in end-pandemic donors and correlated with OC43 S1 and S2-specific IgG titers and reactive B-cells frequencies.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,Serum OC43 neutralization titers were higher in end-pandemic donors and correlated with OC43 S1 and S2-specific IgG titers and reactive B-cells frequencies.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,Serum OC43 neutralization titers were higher in end-pandemic donors and correlated with OC43 S1 and S2-specific IgG titers and reactive B-cells frequencies.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,Serum OC43 neutralization titers were higher in end-pandemic donors and correlated with OC43 S1 and S2-specific IgG titers and reactive B-cells frequencies.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,Serum OC43 neutralization titers were higher in end-pandemic donors and correlated with OC43 S1 and S2-specific IgG titers and reactive B-cells frequencies.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,Serum OC43 neutralization titers were higher in end-pandemic donors and correlated with OC43 S1 and S2-specific IgG titers and reactive B-cells frequencies.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,Serum OC43 neutralization titers were higher in end-pandemic donors and correlated with OC43 S1 and S2-specific IgG titers and reactive B-cells frequencies.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,Serum OC43 neutralization titers were higher in end-pandemic donors and correlated with OC43 S1 and S2-specific IgG titers and reactive B-cells frequencies.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,Serum OC43 neutralization titers were higher in end-pandemic donors and correlated with OC43 S1 and S2-specific IgG titers and reactive B-cells frequencies.,10.1101/2025.09.28.25336743
OC43,OC43,unknown,"However, the SARS-CoV-2/OC43 S2 cross-reactive IgG clones did not independently correlate with OC43 neutralization titers.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"However, the SARS-CoV-2/OC43 S2 cross-reactive IgG clones did not independently correlate with OC43 neutralization titers.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"However, the SARS-CoV-2/OC43 S2 cross-reactive IgG clones did not independently correlate with OC43 neutralization titers.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"However, the SARS-CoV-2/OC43 S2 cross-reactive IgG clones did not independently correlate with OC43 neutralization titers.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"However, the SARS-CoV-2/OC43 S2 cross-reactive IgG clones did not independently correlate with OC43 neutralization titers.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"However, the SARS-CoV-2/OC43 S2 cross-reactive IgG clones did not independently correlate with OC43 neutralization titers.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"However, the SARS-CoV-2/OC43 S2 cross-reactive IgG clones did not independently correlate with OC43 neutralization titers.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"However, the SARS-CoV-2/OC43 S2 cross-reactive IgG clones did not independently correlate with OC43 neutralization titers.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"However, the SARS-CoV-2/OC43 S2 cross-reactive IgG clones did not independently correlate with OC43 neutralization titers.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"However, the SARS-CoV-2/OC43 S2 cross-reactive IgG clones did not independently correlate with OC43 neutralization titers.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"However, the SARS-CoV-2/OC43 S2 cross-reactive IgG clones did not independently correlate with OC43 neutralization titers.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"However, the SARS-CoV-2/OC43 S2 cross-reactive IgG clones did not independently correlate with OC43 neutralization titers.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"However, the SARS-CoV-2/OC43 S2 cross-reactive IgG clones did not independently correlate with OC43 neutralization titers.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"However, the SARS-CoV-2/OC43 S2 cross-reactive IgG clones did not independently correlate with OC43 neutralization titers.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"However, the SARS-CoV-2/OC43 S2 cross-reactive IgG clones did not independently correlate with OC43 neutralization titers.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"However, the SARS-CoV-2/OC43 S2 cross-reactive IgG clones did not independently correlate with OC43 neutralization titers.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"However, the SARS-CoV-2/OC43 S2 cross-reactive IgG clones did not independently correlate with OC43 neutralization titers.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"However, the SARS-CoV-2/OC43 S2 cross-reactive IgG clones did not independently correlate with OC43 neutralization titers.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"However, the SARS-CoV-2/OC43 S2 cross-reactive IgG clones did not independently correlate with OC43 neutralization titers.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"However, the SARS-CoV-2/OC43 S2 cross-reactive IgG clones did not independently correlate with OC43 neutralization titers.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"However, the SARS-CoV-2/OC43 S2 cross-reactive IgG clones did not independently correlate with OC43 neutralization titers.",10.1101/2025.09.28.25336743
OC43,sHCoVs,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
OC43,NL63,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
OC43,NL63,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
sHCoVs,OC43,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
sHCoVs,NL63,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
sHCoVs,OC43,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
sHCoVs,OC43,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
sHCoVs,OC43,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
sHCoVs,OC43,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
sHCoVs,OC43,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
sHCoVs,NL63,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
OC43,NL63,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
OC43,NL63,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
NL63,OC43,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
NL63,OC43,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
NL63,OC43,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
NL63,OC43,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
NL63,OC43,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
NL63,NL63,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
OC43,NL63,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
OC43,NL63,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
OC43,NL63,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
OC43,OC43,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
OC43,NL63,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
OC43,NL63,unknown,"We conclude that the establishment of SARS-CoV-2-specific immune responses altered responses to sHCoVs in our cohort, particularly for OC43 and NL63.",10.1101/2025.09.28.25336743
SARS-CoV-2 infection,infection,unknown,"This study analyzes the composition of the oral microbiota in relation to age, household cohabitation, SARS-CoV-2 infection, and COVID-19 severity among children and adults under home confinement in Barcelona, Spain.",10.1101/2025.09.30.679491
SARS-CoV-2 infection,SARS-CoV-2 infection,unknown,"This study analyzes the composition of the oral microbiota in relation to age, household cohabitation, SARS-CoV-2 infection, and COVID-19 severity among children and adults under home confinement in Barcelona, Spain.",10.1101/2025.09.30.679491
SARS-CoV-2 infection,infection,unknown,"This study analyzes the composition of the oral microbiota in relation to age, household cohabitation, SARS-CoV-2 infection, and COVID-19 severity among children and adults under home confinement in Barcelona, Spain.",10.1101/2025.09.30.679491
infection,SARS-CoV-2 infection,unknown,"This study analyzes the composition of the oral microbiota in relation to age, household cohabitation, SARS-CoV-2 infection, and COVID-19 severity among children and adults under home confinement in Barcelona, Spain.",10.1101/2025.09.30.679491
infection,infection,unknown,"This study analyzes the composition of the oral microbiota in relation to age, household cohabitation, SARS-CoV-2 infection, and COVID-19 severity among children and adults under home confinement in Barcelona, Spain.",10.1101/2025.09.30.679491
SARS-CoV-2 infection,infection,unknown,"This study analyzes the composition of the oral microbiota in relation to age, household cohabitation, SARS-CoV-2 infection, and COVID-19 severity among children and adults under home confinement in Barcelona, Spain.",10.1101/2025.09.30.679491
SARS-CoV-2 infection,infection,unknown,"All 142 adults had a prior confirmed SARS-CoV-2 infection, and 20 (14.08%) of them had a history of severe COVID-19.",10.1101/2025.09.30.679491
SARS-CoV-2 infection,SARS-CoV-2 infection,unknown,"All 142 adults had a prior confirmed SARS-CoV-2 infection, and 20 (14.08%) of them had a history of severe COVID-19.",10.1101/2025.09.30.679491
SARS-CoV-2 infection,infection,unknown,"All 142 adults had a prior confirmed SARS-CoV-2 infection, and 20 (14.08%) of them had a history of severe COVID-19.",10.1101/2025.09.30.679491
infection,SARS-CoV-2 infection,unknown,"All 142 adults had a prior confirmed SARS-CoV-2 infection, and 20 (14.08%) of them had a history of severe COVID-19.",10.1101/2025.09.30.679491
infection,infection,unknown,"All 142 adults had a prior confirmed SARS-CoV-2 infection, and 20 (14.08%) of them had a history of severe COVID-19.",10.1101/2025.09.30.679491
SARS-CoV-2 infection,infection,unknown,"All 142 adults had a prior confirmed SARS-CoV-2 infection, and 20 (14.08%) of them had a history of severe COVID-19.",10.1101/2025.09.30.679491
infection,infection,unknown,SARS-CoV2 infection was detected in 58/265 (21.89%) of children; all of them were asymptomatic.,10.1101/2025.09.30.679491
SARS-CoV-2 infection,infection,unknown,Oral microbiota composition and diversity did not differ by SARS-CoV-2 infection status in children.,10.1101/2025.09.30.679491
SARS-CoV-2 infection,SARS-CoV-2 infection,unknown,Oral microbiota composition and diversity did not differ by SARS-CoV-2 infection status in children.,10.1101/2025.09.30.679491
SARS-CoV-2 infection,infection,unknown,Oral microbiota composition and diversity did not differ by SARS-CoV-2 infection status in children.,10.1101/2025.09.30.679491
infection,SARS-CoV-2 infection,unknown,Oral microbiota composition and diversity did not differ by SARS-CoV-2 infection status in children.,10.1101/2025.09.30.679491
infection,infection,unknown,Oral microbiota composition and diversity did not differ by SARS-CoV-2 infection status in children.,10.1101/2025.09.30.679491
SARS-CoV-2 infection,infection,unknown,Oral microbiota composition and diversity did not differ by SARS-CoV-2 infection status in children.,10.1101/2025.09.30.679491
infection,infection,unknown,"Our study demonstrates that oral microbiota composition in adults varies according to COVID-19 severity, whereas such microbial shifts are not observed in asymptomatic pediatric populations, regardless of infection status.",10.1101/2025.09.30.679491
K,DTLVardef@1696837_HPS_FORMAT_FIGEXP M_FIG,unknown,"Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=138 SRC=""FIGDIR/small/677528v1_ufig1.gif"" ALT=""Figure 1""> View larger version (27K): org.highwire.dtl.DTLVardef@131df69org.highwire.dtl.DTLVardef@1429b6corg.highwire.dtl.DTLVardef@1ea0eacorg.highwire.dtl.DTLVardef@1696837_HPS_FORMAT_FIGEXP M_FIG C_FIG AbstractRNA-Binding proteins (RBPs) play critical roles in host-virus interaction.",10.1101/2025.09.22.677528
U/A,G/C,unknown,"The majority of the RBPs with AU-rich binding motifs are reduced in the variants, while RBPs with mostly GC-rich motifs accumulate more binding positions, suggesting that a single change from U/A to G/C and vice versa can impact RBP- viral interactions.",10.1101/2025.09.22.677528
